FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Kastelein

Research Profile

Disorders

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Julian C van Capelleveen; Mohammad Mahdi Motazacker; Andrea E Bochem; G Kees Hovingh; John J P Kastelein
Genetics of HDL-C: A Causal Link to Atherosclerosis?
John J P Kastelein; Colin J D Ross; Michael R Hayden
From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world.
Brigitte M Sondermeijer; Nicholas J Wareham; S Matthijs Boekholdt; John J P Kastelein; Jamal S Rana; Kay-Tee Khaw
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Kastelein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Julian C van Capelleveen; Mohammad Mahdi Motazacker; Andrea E Bochem; G Kees Hovingh; John J P Kastelein
Genetics of HDL-C: A Causal Link to Atherosclerosis?
Current atherosclerosis reports 2013;15(6):326.
2013: John J P Kastelein; Colin J D Ross; Michael R Hayden
From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world.
Human gene therapy 2013;24(5):472-8.
2013: Brigitte M Sondermeijer; Nicholas J Wareham; S Matthijs Boekholdt; John J P Kastelein; Jamal S Rana; Kay-Tee Khaw
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.
European heart journal 2013;34(18):1350-7.
2013: Paul M Ridker; Jacques Genest; John J P Kastelein; Wolfgang Koenig
C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care.
European heart journal 2013;34(17):1258-61.
2013: Vincenzo Sorrentino; Geesje M Dallinga-Thie; Joep C Defesche; Sigrid W Fouchier; John J P Kastelein; G Kees Hovingh; Mohammad Mahdi Motazacker; Jessica K Nelson; Noam Zelcer
Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein.
European heart journal 2013;34(17):1292-7.
2013: Daniëlla M Oosterveer; Yurii Aulchenko; Joep C Defesche; Albert Hofman; John J P Kastelein; Monique Mulder; Suthesh Sivapalaratnam; André G Uitterlinden; Leonie van der Zee; Cornelia M van Duijn; Jorie Versmissen; Mojgan Yazdanpanah; Eric J G Sijbrands
Low-density lipoprotein receptor mutations generate synthetic genome-wide associations.
European journal of human genetics : EJHG 2013;21(5):563-6.
2013: G Kees Hovingh; John J P Kastelein; Michael H Davidson; Anne M O'Connor
Diagnosis and treatment of familial hypercholesterolaemia.
European heart journal 2013;34(13):962-71.
2013: Joost Besseling; John J P Kastelein; Julian van Capelleveen; G Kees Hovingh
LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?
Drugs 2013;73(4):293-301.
2013: Jan Westerink; Dick C Basart; Blai Coll; John E Deanfield; Ben P Imholz; John J P Kastelein; Wilko Spiering; Frank L J Visseren
High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study.
Atherosclerosis 2013;227(1):118-24.
2013: David D Waters; S Matthijs Boekholdt; Andrei Breazna; David A DeMicco; Jennifer E Ho; John J P Kastelein; Michael Messig; Terje R Pedersen
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Journal of the American College of Cardiology 2013;61(2):148-52.
2013: Andrea E Bochem; Geesje M Dallinga-Thie; Eric de Groot; Raphaël Duivenvoorden; Adriaan G Holleboom; G Kees Hovingh; John J P Kastelein; Mohammad Mahdi Motazacker; Aart J Nederveen; Diederik F van Wijk; Erik S G Stroes
ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden.
European heart journal 2013;34(4):286-91.
2012: Bas van den Bogaard; Raphaël Duivenvoorden; Adriaan G Holleboom; G Kees Hovingh; Barbara A Hutten; John J P Kastelein; Jan Albert Kuivenhoven; Erik S G Stroes; Bert-Jan H van den Born
Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness.
Atherosclerosis 2012;225(2):481-5.
2012: Adriaan G Holleboom; G Kees Hovingh; Barbara A Hutten; John J P Kastelein; Angeliki Chroni; Georgios Daniil; Xiaoming Fu; Stanley L Hazen; Alinda W Schimmel; Erik S G Stroes; Sotirios Tsimikas; Joseph L Witztum; Renliang Zhang; Jan Albert Kuivenhoven
Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations.
Arteriosclerosis, thrombosis, and vascular biology 2012;32(12):3066-75.
2012: Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
The PCSK9 decade.
Journal of lipid research 2012;53(12):2515-24.
2012: Philip J Barter; Mohan S Beltangady; S Matthijs Boekholdt; David A DeMicco; William T Duggan; John J P Kastelein; William C Ports; Kerry-Anne Rye; Charles L Shear
Relationship between atorvastatin dose and the harm caused by torcetrapib.
Journal of lipid research 2012;53(11):2436-42.
2012: Michiel L Bots; Hester M den Ruijter; Damiano Baldassarre; John J P Kastelein; Daniel H O'Leary; Sanne A E Peters; James H Revkin; James H Stein; Allen J Taylor; Charles H Tegeler; Diederick E Grobbee
Rate of change in carotid intima-media thickness and vascular events: meta-analyses can not solve all the issues. A point of view.
Journal of hypertension 2012;30(9):1690-6.
2012: Pythia T Nieuwkerk; Mirjam A G Sprangers; Maud N Vissers; Hanneke C J M de Haes; Phillip Greggers-Peusch; John J P Kastelein; Léon P M Knape; Mirjam Locadia; Melchior C Nierman; Erik S G Stroes
Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk.
The American journal of cardiology 2012;110(5):666-72.
2012: Roeland Huijgen; Joep C Defesche; Iris Kindt; John J P Kastelein
Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants.
European heart journal 2012;33(18):2325-30.
2012: Roeland Huijgen; Barbara A Hutten; John J P Kastelein; Iris Kindt; Sietske J M Homsma; Maud N Vissers; Jan L A van Rijckevorsel
Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study.
European journal of human genetics : EJHG 2012;20(7):722-8.
2012: Hans J Avis; Roeland Huijgen; Thomas H Janssen; John J P Kastelein; Iris Kindt; D Meeike Kusters; Maud N Vissers; Albert Wiegman; Frits A Wijburg; Barbara A Hutten
Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program.
The Journal of pediatrics 2012;161(1):99-103.
2012: Benoit J Arsenault; S Matthijs Boekholdt; Jean-Claude Tardif; John J P Kastelein
De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?
European heart journal 2012;33(13):1548-50.
2012: Maartje E Visser; Joseph L Witztum; Erik S G Stroes; John J P Kastelein
Antisense oligonucleotides for the treatment of dyslipidaemia.
European heart journal 2012;33(12):1451-8.
2012: Roeland Huijgen; Barbara A Hutten; Iris Kindt; Maud N Vissers; John J P Kastelein
Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH.
Circulation. Cardiovascular genetics 2012;5(3):354-9.
2012: Mohammad Mahdi Motazacker; Jorge Peter; James Pirruccello; Noam Zelcer; Stacey Gabriel; G Kees Hovingh; Roeland Huijgen; John J P Kastelein; Sekar Kathiresan; Jan Albert Kuivenhoven; Joep C Defesche; Ron Do; Sigrid W Fouchier
Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia.
European heart journal 2012;33(11):1360-6.
2012: Roeland Huijgen; John J P Kastelein; Francine Petrides; Kerry-Anne Rye; Fatiha Tabet; Benoit J Arsenault; Weihang Bao; Philip J Barter; S Matthijs Boekholdt; Jean-Michel Davaine; David A DeMicco; Gilles Lambert
Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.
Journal of the American College of Cardiology 2012;59(20):1778-84.
2012: Maartje E Visser; Gilbert Wagener; Mieke D Trip; Joanne Verheij; Brenda F Baker; Dick C G Basart; Ulrich H W Beuers; Joanne M Donovan; Richard S Geary; John J P Kastelein; Aart J Nederveen; Erik S G Stroes
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.
European heart journal 2012;33(9):1142-9.
2012: Samia Mora; Børge G Nordestgaard; S Matthijs Boekholdt; Robert J Glynn; John J P Kastelein; Paul M Ridker
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Journal of the American College of Cardiology 2012;59(17):1521-8.
2012: Samia Mora; Nanette K Wenger; Benoit J Arsenault; S Matthijs Boekholdt; Andrei Breazna; Prakash Deedwania; David A Demicco; John J P Kastelein; David D Waters
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
Circulation 2012;125(16):1979-87.
2012: Stephen J Nicholls; Norman C Wong; Christie M Ballantyne; Philip J Barter; Marilyn R N Borgman; H Bryan Brewer; Allan Gordon; Jan Johannson; John J P Kastelein; Steven E Nissen
ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2012;26(2):181-7.
2012: Thomas F Lüscher; Thomas Münzel; Stefano Taddei; John E Deanfield; J Wouter Jukema; David Kallend; Juan-Carlos Kaski; John J P Kastelein
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
European heart journal 2012;33(7):857-65.
2012: Jamal S Rana; S Matthijs Boekholdt; John J P Kastelein; Prediman K Shah
The role of non-HDL cholesterol in risk stratification for coronary artery disease.
Current atherosclerosis reports 2012;14(2):130-4.
2012: S Matthijs Boekholdt; Michael B Clearfield; Helen M Colhoun; David A DeMicco; John R Downs; Paul Durrington; Antonio M Gotto; Graham A Hitman; John C LaRosa; Samia Mora; Paul J Nestel; Terje R Pedersen; Paul M Ridker; R John Simes; Andrew M Tonkin; K M A Welch; Aeilko H Zwinderman; Benoit J Arsenault; John J P Kastelein
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
JAMA : the journal of the American Medical Association 2012;307(12):1302-9.
2012: Ties A Mulders; Alan D Guerci; John J P Kastelein; Suthesh Sivapalaratnam; Erik S G Stroes; Sara-Joan Pinto-Sietsma
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.
JACC. Cardiovascular imaging 2012;5(3):252-60.
2012: Ian Tietjen; Elden Chan; G Kees Hovingh; John J P Kastelein; Annick Legendre; Maryanne Mattice; Jason McEwen; Christopher C Radomski; Roshni Singaraja; Michael R Hayden
Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT.
Biochimica et biophysica acta 2012;1821(3):416-24.
2012: Benoit J Arsenault; Philip Barter; S Matthijs Boekholdt; Aurobindo Chatterjee; Prakash Deedwania; David A DeMicco; G Kees Hovingh; Craig L Hyde; John J P Kastelein; John C LaRosa; Terje R Pedersen; David D Waters
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
Circulation. Cardiovascular genetics 2012;5(1):51-7.
2012: Stephen J Nicholls; Robert S Rosenson; Gregory Schwartz; David D Waters; Dianna Bash; Matthew A Cavender; John J P Kastelein; Colin Hislop
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2012;26(1):71-5.
2012: Ian Tietjen; Amina Barhdadi; Elden Chan; Marie-Pierre Dubé; Patrick L Franchini; G Kees Hovingh; John J P Kastelein; Annick Legendre; Maryanne Mattice; Jason McEwen; Christopher C Radomski; Roshni R Singaraja; Michael R Hayden
Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol.
PloS one 2012;7(8):e37437.
2012: Suthesh Sivapalaratnam; Brigitte M Sondermeijer; Nicholas A Watkins; Hanneke Basart; Esther E Creemers; Alison H Goodall; Kees Hovingh; John J P Kastelein; Unni Krishnan; Stepanie Maiwald; Willem H Ouwehand; Sara-Joan Pinto-Sietsma; Augusto Rendon; Mieke D Trip
Monocyte gene expression signature of patients with early onset coronary artery disease.
PloS one 2012;7(2):e32166.
2012: Brigitte M Sondermeijer; Erik S G Stroes; Marcel Th B Twickler; Geesje M Dallinga-Thie; Eric Fliers; Eric J F Franssen; Barbara A Hutten; John J P Kastelein; Christian F Klein Twennaar; Mireille J Serlie
Infusion of a lipid emulsion in healthy men decreases the serotonergic response.
Neuroendocrinology 2012;95(4):325-31.
2011: Raphaël Duivenvoorden; Adriaan G Holleboom; G Kees Hovingh; Barbara A Hutten; John J P Kastelein; Jan Albert Kuivenhoven; Aart J Nederveen; Alinda W Schimmel; Eric de Groot; Bas van den Bogaard; Erik S G Stroes
Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected].
Journal of the American College of Cardiology 2011;58(24):2481-7.
2011: Jorie Versmissen; Ranitha Vongpromek; Leonie van Vark-van der Zee; Tim Vanmierlo; Jimmy F P Berbée; Adriana C Blommesteijn-Touw; Joep C Defesche; Menno Hoekstra; John J P Kastelein; Monique Mulder; Daniëlla M Oosterveer; Ruud Out; Eric J G Sijbrands
Apolipoprotein isoform E4 does not increase coronary heart disease risk in carriers of low-density lipoprotein receptor mutations.
Circulation. Cardiovascular genetics 2011;4(6):655-60.
2011: Jorie Versmissen; Ilse P G Botden; Joep C Defesche; Thea C Heil; Roeland Huijgen; John J P Kastelein; Janneke G Langendonk; Anouk Muntz; Daniëlla M Oosterveer; Arend F L Schinkel; Eric J G Sijbrands
Maternal inheritance of familial hypercholesterolemia caused by the V408M low-density lipoprotein receptor mutation increases mortality.
Atherosclerosis 2011;219(2):690-3.
2011: Stephen J Nicholls; Mingyuan Shao; Ming-Dauh Wang; H Bryan Brewer; Bo Hu; John J P Kastelein; Kathryn A Krueger; Ellen McErlean; Steven E Nissen
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2011;306(19):2099-109.
2011: Adriaan G Holleboom; G Kees Hovingh; John J P Kastelein; Jan Albert Kuivenhoven; Frank Peelman; Jorge Peter; Alinda W Schimmel; Erik S Stroes; Joep C Defesche; Mohammad Mahdi Motazacker
High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutations.
Human mutation 2011;32(11):1290-8.
2011: Lysette N Broekhuizen; A Crozier; Paul G Hugenholtz; B A Hutten; John J P Kastelein; Wolfgang Koenig; A Stalmach; Diederik F van Wijk; Jurgen van Teeffelen; Erik S G Stroes
Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors.
The British journal of nutrition 2011;106(9):1416-22.
2011: Fatima Akdim; Brenda F Baker; JoAnn D Flaim; Rainard Fuhr; Richard S Geary; John Su; Diane L Tribble; Mark K Wedel; Rosie Yu; John J P Kastelein
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.
European heart journal 2011;32(21):2650-9.
2011: Jakub J Regieli; Yolanda van der Graaf; Aeilko H Zwinderman; Pieter A Doevendans; Diederick E Grobbee; John J P Kastelein; J Wouter Jukema
ABCA1 impacts athero-thrombotic risk and 10-year survival in a contemporary secondary prevention setting.
Atherosclerosis 2011;218(2):457-63.
2011: Amir Ravandi; Philippa J Talmud; Alain Tedgui; Joelle Benessiano; S Matthijs Boekholdt; John J P Kastelein; Kay-Tee Khaw; Ziad Mallat; Elizabeth R Miller; Nicholas J Wareham; Joseph L Witztum; Sotirios Tsimikas
Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.
Journal of lipid research 2011;52(10):1829-36.
2011: Remco Franssen; Houshang Monajemi; Erik S G Stroes; John J P Kastelein
Obesity and dyslipidemia.
The Medical clinics of North America 2011;95(5):893-902.
2011: Pernette R W de Sauvage Nolting; D Meeike Kusters; Barbara A Hutten; John J P Kastelein
Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease?
Journal of lipid research 2011;52(9):1755-9.
2011: Philip J Barter; S Matthijs Boekholdt; Andrei Breazna; Kerry-Anne Rye; Jean-Claude Tardif; David D Waters; John J P Kastelein
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Circulation 2011;124(5):555-62.
2011: Roeland Huijgen; Eric de Groot; John J P Kastelein; Iris Kindt; Mieke D Trip; Maud N Vissers; Barbara A Hutten
Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes.
Circulation. Cardiovascular genetics 2011;4(4):413-7.
2011: Daniel H O'Leary; Anne Q Reuwer; Frank L J Visseren; Salvatore M Zabbatino; Rong Zhou; Michael W Brown; John E Deanfield; Jean-Pierre Després; Bernard Job; John J P Kastelein; Steven E Nissen
Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.
Heart (British Cardiac Society) 2011;97(14):1143-50.
2011: David Preiss; Marc S Sabatine; Naveed Sattar; Sreenivasa Rao Kondapally Seshasai; Matti J Tikkanen; David D Waters; Paul Welsh; Philip Barter; Michael A Blazing; Eugene Braunwald; Christopher P Cannon; James A de Lemos; David A DeMicco; Jennifer E Ho; John J P Kastelein; Sabina A Murphy; Terje R Pedersen; Kausik K Ray
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
JAMA : the journal of the American Medical Association 2011;305(24):2556-64.
2011: Paul M Ridker; Wolfgang Koenig; John J P Kastelein
C-reactive protein in the Heart Protection Study.
Lancet 2011;377(9781):1918; author reply 1918-9.
2011: Benoit J Arsenault; S Matthijs Boekholdt; John J P Kastelein
Lipid parameters for measuring risk of cardiovascular disease.
Nature reviews. Cardiology 2011;8(4):197-206.
2011: Benoit J Arsenault; S Matthijs Boekholdt; John J P Kastelein
Varespladib: targeting the inflammatory face of atherosclerosis.
European heart journal 2011;32(8):923-6.
2011: Anouk van der Graaf; Hans J Avis; D Meeike Kusters; Maud N Vissers; Barbara A Hutten; Joep C Defesche; Roeland Huijgen; Sigrid W Fouchier; Frits A Wijburg; John J P Kastelein; Albert Wiegman
Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children.
Circulation 2011;123(11):1167-73.
2011: Allen J Taylor; Michiel L Bots; John J P Kastelein
Vascular disease: meta-regression of CIMT trials-data in, garbage out.
Nature reviews. Cardiology 2011;8(3):128-30.
2011: Stephen J Nicholls; Allan Gordon; Jan Johansson; Kathy Wolski; Christie M Ballantyne; John J P Kastelein; Allen Taylor; Marilyn Borgman; Steven E Nissen
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Journal of the American College of Cardiology 2011;57(9):1111-9.
2011: Anne Q Reuwer; Marco van Eijk; Felicia M Houttuijn-Bloemendaal; Chris M van der Loos; Nike Claessen; Peter Teeling; John J P Kastelein; Jörg Hamann; Vincent Goffin; Jan H von der Thüsen; Marcel Th B Twickler; Jan Aten
The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis?
The Journal of endocrinology 2011;208(2):107-17.
2011: Bas van den Bogaard; Bert-Jan H van den Born; Rana Fayyad; David D Waters; David A DeMicco; John C LaRosa; John J P Kastelein; Ingar Holme
On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study.
European journal of clinical investigation 2011;41(2):134-42.
2011: Jorie Versmissen; Daniëlla M Oosterveer; Mojgan Yazdanpanah; Monique Mulder; Abbas Dehghan; Joep C Defesche; John J P Kastelein; Eric J G Sijbrands
A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients.
European heart journal 2011;32(4):469-75.
2011: Jamal S Rana; Benoit J Arsenault; Jean-Pierre Després; Mélanie Côté; Philippa J Talmud; Ewa Ninio; J Wouter Jukema; Nicholas J Wareham; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women.
European heart journal 2011;32(3):336-44.
2011: Menno Vergeer; Suzanne J A Korporaal; Remco Franssen; Illiana Meurs; Ruud Out; G Kees Hovingh; Menno Hoekstra; Jeroen A Sierts; Geesje M Dallinga-Thie; Mohammad Mahdi Motazacker; Adriaan G Holleboom; Theo Van berkel; John J P Kastelein; Miranda van Eck; Jan Albert Kuivenhoven
Genetic variant of the scavenger receptor BI in humans.
The New England journal of medicine 2011;364(2):136-45.
2011: Benoit J Arsenault; Philip Barter; David A DeMicco; Weihang Bao; Gregory M Preston; John C LaRosa; Scott M Grundy; Prakash Deedwania; Heiner Greten; Nanette K Wenger; James Shepherd; David D Waters; John J P Kastelein
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
Journal of the American College of Cardiology 2011;57(1):63-9.
2011: Sung Kee Ryu; Barbara A Hutten; Maud N Vissers; Albert Wiegman; John J P Kastelein; Sotirios Tsimikas
Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Journal of clinical lipidology 2011;5(1):50-6.
2011: John J P Kastelein; Raphaël Duivenvoorden; John Deanfield; Eric de Groot; J Wouter Jukema; Juan-Carlos Kaski; Thomas Münzel; Stefano Taddei; Valerie Lehnert; Tracy Burgess; David Kallend; Thomas F Lüscher
Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation.
Current medical research and opinion 2011;27(1):141-50.
2010: G Kees Hovingh; Andrea E Bochem; John J P Kastelein
Apolipoprotein A-I mimetic peptides.
Current opinion in lipidology 2010;21(6):481-6.
2010: Suthesh Sivapalaratnam; S Matthijs Boekholdt; Mieke D Trip; Manjinder S Sandhu; Robert Luben; John J P Kastelein; Nicholas J Wareham; Kay-Tee Khaw
Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study.
Heart (British Cardiac Society) 2010;96(24):1985-9.
2010: Anouk van der Graaf; Maud N Vissers; Daniel Gaudet; Diane Brisson; Suthesh Sivapalaratnam; Tessa J Roseboom; Angelique C M Jansen; John J P Kastelein; Barbara A Hutten
Dyslipidemia of mothers with familial hypercholesterolemia deteriorates lipids in adult offspring.
Arteriosclerosis, thrombosis, and vascular biology 2010;30(12):2673-7.
2010: Marietta Charakida; Stefano Masi; Thomas F Lüscher; John J P Kastelein; John E Deanfield
Assessment of atherosclerosis: the role of flow-mediated dilatation.
European heart journal 2010;31(23):2854-61.
2010: Benoit J Arsenault; Jean-Pierre Després; Erik S G Stroes; Nicholas J Wareham; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Lipid assessment, metabolic syndrome and coronary heart disease risk.
European journal of clinical investigation 2010;40(12):1081-93.
2010: Lily Jakulj; Maud N Vissers; Michael W T Tanck; Barbara A Hutten; Frans Stellaard; John J P Kastelein; Geesje M Dallinga-Thie
ABCG5/G8 polymorphisms and markers of cholesterol metabolism: systematic review and meta-analysis.
Journal of lipid research 2010;51(10):3016-23.
2010: Benoit J Arsenault; Isabelle Lemieux; Jean-Pierre Després; Nicholas J Wareham; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2010;182(13):1427-32.
2010: Sotirios Tsimikas; Ziad Mallat; Philippa J Talmud; John J P Kastelein; Nicholas J Wareham; Manjinder S Sandhu; Elizabeth R Miller; Joelle Benessiano; Alain Tedgui; Joseph L Witztum; Kay-Tee Khaw; S Matthijs Boekholdt
Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.
Journal of the American College of Cardiology 2010;56(12):946-55.
2010: Jamal S Rana; Maartje E Visser; Benoit J Arsenault; Jean-Pierre Després; Erik S G Stroes; John J P Kastelein; Nicholas J Wareham; S Matthijs Boekholdt; Kay-Tee Khaw
Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.
International journal of cardiology 2010;143(3):399-404.
2010: Paul M Ridker; Jean G Macfadyen; Børge G Nordestgaard; Wolfgang Koenig; John J P Kastelein; Jacques Genest; Robert J Glynn
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk".
Circulation. Cardiovascular quality and outcomes 2010;3(5):447-52.
2010: Radjesh J Bisoendial; S Matthijs Boekholdt; Menno Vergeer; Erik S G Stroes; John J P Kastelein
C-reactive protein is a mediator of cardiovascular disease.
European heart journal 2010;31(17):2087-91.
2010: Soner Dogan; Raphaël Duivenvoorden; Diederick E Grobbee; John J P Kastelein; Charles L Shear; Greg W Evans; Frank L Visseren; Michiel L Bots
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
Annals of medicine 2010;42(6):447-64.
2010: Raphaël Duivenvoorden; Ed Vanbavel; Eric de Groot; Erik S G Stroes; Jonathan A Disselhorst; Barbara A Hutten; Johan S Laméris; John J P Kastelein; Aart J Nederveen
Endothelial shear stress: a critical determinant of arterial remodeling and arterial stiffness in humans--a carotid 3.0-T MRI study.
Circulation. Cardiovascular imaging 2010;3(5):578-85.
2010: Lily Jakulj; Maud N Vissers; Cindy P van Roomen; Jelske N van der Veen; Carlos L J Vrins; Cindy Kunne; Frans Stellaard; John J P Kastelein; Albert K Groen
Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice.
FEBS letters 2010;584(16):3625-8.
2010: Menno Vergeer; S Matthijs Boekholdt; Manjinder S Sandhu; Sally L Ricketts; Nicholas J Wareham; Morris J Brown; Ulf de Faire; Karin Leander; Bruna Gigante; Maryam Kavousi; Albert Hofman; Andre G Uitterlinden; Cornelia M van Duijn; Jacqueline C M Witteman; J Wouter Jukema; Eric E Schadt; Ellen van der Schoot; John J P Kastelein; Kay-Tee Khaw; Robin P F Dullaart; Arie Van Tol; Mieke D Trip; Geesje M Dallinga-Thie
Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility.
Circulation 2010;122(5):470-7.
2010: Terje R Pedersen; Nilo B Cater; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Christina Lindahl; Michael Szarek
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
The American journal of cardiology 2010;106(3):354-9.
2010: Menno Vergeer; Danny M Cohn; S Matthijs Boekholdt; Manjinder S Sandhu; Hester M Prins; Sally L Ricketts; Nicholas J Wareham; John J P Kastelein; Kay-Tee Khaw; Pieter W Kamphuisen; Geesje M Dallinga-Thie
Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT.
Atherosclerosis 2010;211(2):558-64.
2010: Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
Journal of lipid research 2010;51(8):2058-73.
2010: Paul M Ridker; Jacques Genest; S Matthijs Boekholdt; Peter Libby; Antonio M Gotto; Børge G Nordestgaard; Samia Mora; Jean G MacFadyen; Robert J Glynn; John J P Kastelein
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Lancet 2010;376(9738):333-9.
2010: Menno Vergeer; Rong Zhou; Michiel L Bots; Raphaël Duivenvoorden; Joerg Koglin; Fatima Akdim; Yale B Mitchel; Roeland Huijgen; Aditi Sapre; Eric de Groot; Eric J G Sijbrands; Richard C Pasternak; Claude Gagné; A David Marais; Christie M Ballantyne; Jonathan L Isaacsohn; Anton F Stalenhoef; John J P Kastelein
Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies.
Circulation. Cardiovascular imaging 2010;3(4):398-404.
2010: Diederik F van Wijk; Sander I van Leuven; Manjinder S Sandhu; Michael W T Tanck; Barbara A Hutten; Nicholas J Wareham; John J P Kastelein; Erik S G Stroes; Kay-Tee Khaw; S Matthijs Boekholdt
Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2010;30(7):1460-6.
2010: Sander I van Leuven; Diederik F van Wijk; Oscar L Volger; Jean-Paul P M de Vries; Chris M van der Loos; Dominique V P de Kleijn; Anton J G Horrevoets; Paul P Tak; Allard C van der Wal; Onno J de Boer; Gerard Pasterkamp; Michael R Hayden; John J P Kastelein; Erik S G Stroes
Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis.
Atherosclerosis 2010;211(1):231-6.
2010: Geesje M Dallinga-Thie; Remco Franssen; Hans L Mooij; Maartje E Visser; H Carlijne Hassing; Frank Peelman; John J P Kastelein; Miklós Péterfy; Max Nieuwdorp
The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight.
Atherosclerosis 2010;211(1):1-8.
2010: Roeland Huijgen; Iris Kindt; Sigrid W Fouchier; Joep C Defesche; Barbara A Hutten; John J P Kastelein; Maud N Vissers
Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia.
Human mutation 2010;31(6):752-60.
2010: Fatima Akdim; Maartje E Visser; Diane L Tribble; Brenda F Baker; Erik S G Stroes; Rosie Yu; Joann D Flaim; John Su; Evan A Stein; John J P Kastelein
Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
The American journal of cardiology 2010;105(10):1413-9.
2010: Benoit J Arsenault; Isabelle Lemieux; Jean-Pierre Després; Nicholas J Wareham; Erik S G Stroes; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size.
Clinical chemistry 2010;56(5):789-98.
2010: Soner Dogan; Raphaël Duivenvoorden; Diederick E Grobbee; John J P Kastelein; Charles L Shear; Gregory W Evans; Frank L Visseren; Michiel L Bots
Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials.
Journal of atherosclerosis and thrombosis 2010;17(5):526-35.
2010: Maartje E Visser; Fatima Akdim; Diane L Tribble; Aart J Nederveen; T Jesse Kwoh; John J P Kastelein; Mieke D Trip; Erik S G Stroes
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.
Journal of lipid research 2010;51(5):1057-62.
2010: Fatima Akdim; Erik S G Stroes; Eric J G Sijbrands; Diane L Tribble; Mieke D Trip; J Wouter Jukema; Joann D Flaim; John Su; Rosie Yu; Brenda F Baker; Mark K Wedel; John J P Kastelein
Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.
Journal of the American College of Cardiology 2010;55(15):1611-8.
2010: Roeland Huijgen; Evertine J Abbink; Eric Bruckert; Anton F H Stalenhoef; BP Imholz; Paul N Durrington; Mieke D Trip; Mats Eriksson; Frank L J Visseren; Juergen R Schaefer; John J P Kastelein
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.
Clinical therapeutics 2010;32(4):615-25.
2010: Menno Vergeer; Liam R Brunham; Joris Koetsveld; Janine K Kruit; C Bruce Verchere; John J P Kastelein; Michael R Hayden; Erik S G Stroes
Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction.
Diabetes care 2010;33(4):869-74.
2010: Daniëlla M Oosterveer; Jorie Versmissen; Mojgan Yazdanpanah; Joep C Defesche; John J P Kastelein; Eric J G Sijbrands
The risk of tendon xanthomas in familial hypercholesterolaemia is influenced by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein oxidation pathway.
European heart journal 2010;31(8):1007-12.
2010: Raphaël Duivenvoorden; Menno Vergeer; John J P Kastelein
Niacin compared with ezetimibe.
The New England journal of medicine 2010;362(11):1046-7; author reply 1048.
2010: Hans J Avis; Barbara A Hutten; Claude Gagné; Gisle Langslet; Brian W McCrindle; Albert Wiegman; Judith Hsia; John J P Kastelein; Evan A Stein
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
Journal of the American College of Cardiology 2010;55(11):1121-6.
2010: Radjesh J Bisoendial; Erik S G Stroes; John J P Kastelein; Paul Peter Tak
Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins.
Nature reviews. Rheumatology 2010;6(3):157-64.
2010: Benoit J Arsenault; Jamal S Rana; Isabelle Lemieux; Jean-Pierre Després; Nicholas J Wareham; John J P Kastelein; S Matthijs Boekholdt; Kay-Tee Khaw
Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study.
Atherosclerosis 2010;209(1):261-5.
2010: Anne Q Reuwer; Paul J H M Reuwer; Joris A van der Post; Maarten J Cramer; John J P Kastelein; Marcel Th B Twickler
Prolactin fragmentation by trophoblastic matrix metalloproteinases as a possible contributor to peripartum cardiomyopathy and pre-eclampsia.
Medical hypotheses 2010;74(2):348-52.
2010: S Matthijs Boekholdt; John J P Kastelein
C-reactive protein and cardiovascular risk: more fuel to the fire.
Lancet 2010;375(9709):95-6.
2010: Roeland Huijgen; Iris Kindt; Sjoerd B J Verhoeven; Eric J G Sijbrands; Maud N Vissers; John J P Kastelein; Barbara A Hutten
Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
PloS one 2010;5(2):e9220.
2009: Benoit J Arsenault; Jamal S Rana; Erik S G Stroes; Jean-Pierre Després; Prediman K Shah; John J P Kastelein; Nicholas J Wareham; S Matthijs Boekholdt; Kay-Tee Khaw
Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.
Journal of the American College of Cardiology 2009;55(1):35-41.
2009: Matti J Tikkanen; Michael Szarek; Rana Fayyad; Ingar Holme; Nilo B Cater; Ole Faergeman; John J P Kastelein; Anders G Olsson; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
Journal of the American College of Cardiology 2009;54(25):2353-7.
2009: Karim El Harchaoui; Remco Franssen; G Kees Hovingh; Radjesh J Bisoendial; Frans Stellaard; Folkert Kuipers; John J P Kastelein; Jan Albert Kuivenhoven; Erik S G Stroes; Albert K Groen
Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia.
Atherosclerosis 2009;207(2):614-6.
2009: John J P Kastelein; Michiel Bots
Statin therapy with ezetimibe or niacin in high-risk patients.
The New England journal of medicine 2009;361(22):2180-3.
2009: Aart C Strang; G Kees Hovingh; Erik S G Stroes; John J P Kastelein
The genetics of high-density lipoprotein metabolism: clinical relevance for therapeutic approaches.
The American journal of cardiology 2009;104(10 Suppl):22E-31E.
2009: Paul M Ridker; Jean G MacFadyen; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Circulation. Cardiovascular quality and outcomes 2009;2(6):616-23.
2009: Katrijn L Rensing; John J P Kastelein; Marcel Twickler
Is insulin the preferred compound in lowering glucose levels in patients after a myocardial infarction?
Archives of internal medicine 2009;169(17):1636-7; author reply 1637-8.
2009: Daniëlla M Oosterveer; Jorie Versmissen; Mojgan Yazdanpanah; Jeroen B van der Net; Joep C Defesche; John J P Kastelein; Eric J G Sijbrands
5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia.
Atherosclerosis 2009;206(1):223-7.
2009: Raphaël Duivenvoorden; Eric de Groot; Erik S G Stroes; John J P Kastelein
Surrogate markers in clinical trials--challenges and opportunities.
Atherosclerosis 2009;206(1):8-16.
2009: Benoit J Arsenault; Isabelle Lemieux; Jean-Pierre Després; Pascale Gagnon; Nicholas J Wareham; Erik S G Stroes; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.
Atherosclerosis 2009;206(1):276-81.
2009: Ole Faergeman; Ingar Holme; Rana Fayyad; Sonal Bhatia; Scott M Grundy; John J P Kastelein; John C LaRosa; Mogens Lytken Larsen; Christina Lindahl; Anders G Olsson; Matti J Tikkanen; David D Waters; Terje R Pedersen
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease.
The American journal of cardiology 2009;104(4):459-63.
2009: Anne Q Reuwer; Marcel Th B Twickler; Barbara A Hutten; Frederique W Molema; Nicholas J Wareham; Geesje M Dallinga-Thie; Roman Bogorad; Vincent Goffin; Mijke Smink-Bol; John J P Kastelein; S Matthijs Boekholdt; Kay-Tee Khaw
Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women.
Circulation. Cardiovascular genetics 2009;2(4):389-95.
2009: Ingar Holme; Timo E Strandberg; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).
Atherosclerosis 2009;205(2):522-7.
2009: Bregje van Zaane; Anne Q Reuwer; Harry R Büller; John J P Kastelein; V E A Gerdes; Marcel Th B Twickler
Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?
Seminars in thrombosis and hemostasis 2009;35(5):478-87.
2009: Evan A Stein; Erik S G Stroes; George Steiner; Brendan M Buckley; Alessandro M Capponi; Tracy Burgess; Eric J Niesor; David Kallend; John J P Kastelein
Safety and tolerability of dalcetrapib.
The American journal of cardiology 2009;104(1):82-91.
2009: Raphaël Duivenvoorden; Eric de Groot; Hamid Afzali; Ed T Vanbavel; Onno J de Boer; Johan S Laméris; Zahi A Fayad; Erik S G Stroes; John J P Kastelein; Aart J Nederveen
Comparison of in vivo carotid 3.0-T magnetic resonance to B-mode ultrasound imaging and histology in a porcine model.
JACC. Cardiovascular imaging 2009;2(6):744-50.
2009: Anne Q Reuwer; Rienk Nieuwland; Isabelle Fernandez; Vincent Goffin; Claudia M van Tiel; Marianne C L Schaap; René Berckmans; John J P Kastelein; Marcel Th B Twickler
Prolactin does not affect human platelet aggregation or secretion.
Thrombosis and haemostasis 2009;101(6):1119-27.
2009: Radjesh J Bisoendial; Rakesh S Birjmohun; Fatima Akdim; Cornelis van 't Veer; C Arnold Spek; Daniel Hartman; Eric de Groot; Danute M Bankaitis-Davis; John J P Kastelein; Erik S G Stroes
C-reactive protein elicits white blood cell activation in humans.
The American journal of medicine 2009;122(6):582.e1-9.
2009: Anne G Semb; Thor Ueland; Pål Aukrust; Nicholas J Wareham; Robert Luben; Lars Gullestad; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(6):975-80.
2009: Ingar Holme; Michael Szarek; Nilo B Cater; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2009;16(3):315-20.
2009: Anne P Beigneux; Remco Franssen; André Bensadoun; Peter Gin; Kristan Melford; Jorge Peter; Rosemary Walzem; Michael M Weinstein; Brandon S J Davies; Jan A Kuivenhoven; John J P Kastelein; Loren G Fong; Geesje M Dallinga-Thie; Stephen G Young
Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(6):956-62.
2009: Kristel C M C Koeijvoets; Jeroen B van der Net; Geesje M Dallinga-Thie; Ewout W Steyerberg; Ronald P Mensink; John J P Kastelein; Eric J G Sijbrands; Jogchum Plat
ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia.
Atherosclerosis 2009;204(2):453-8.
2009: Timo E Strandberg; Ingar Holme; Ole Faergeman; John J P Kastelein; Christina Lindahl; Mogens Lytken Larsen; Anders G Olsson; Terje R Pedersen; Matti J Tikkanen
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
The American journal of cardiology 2009;103(10):1381-5.
2009: Peter Henneman; Femke van der Sman-de Beer; Payman Hanifi Moghaddam; Petra Huijts; Anton F H Stalenhoef; John J P Kastelein; C.M. Duijn; Louis M Havekes; Rune R Frants; Ko Willems van Dijk; August Smelt
The expression of type III hyperlipoproteinemia: involvement of lipolysis genes.
European journal of human genetics : EJHG 2009;17(5):620-8.
2009: Robert J Glynn; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Paul M Ridker
A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
The New England journal of medicine 2009;360(18):1851-61.
2009: John F Thompson; Craig L Hyde; Linda S Wood; Sara A Paciga; David Hinds; David R Cox; G Kees Hovingh; John J P Kastelein
Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort.
Circulation. Cardiovascular genetics 2009;2(2):173-81.
2009: Jeroen B van der Net; Jorie Versmissen; Daniëlla M Oosterveer; Joep C Defesche; Mojgan Yazdanpanah; Bradley E Aouizerat; Ewout W Steyerberg; Mary J Malloy; Clive R Pullinger; John P Kane; John J P Kastelein; Eric J G Sijbrands
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia.
Atherosclerosis 2009;203(2):472-8.
2009: Marijn C Meuwese; Eric de Groot; Raphaël Duivenvoorden; Mieke D Trip; Leiv Ose; Frans J Maritz; Dick C G Basart; John J P Kastelein; Rafik Habib; Michael H Davidson; Aeilko H Zwinderman; Lee R Schwocho; Evan A Stein
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
JAMA : the journal of the American Medical Association 2009;301(11):1131-9.
2009: Matti J Tikkanen; Ingar Holme; Nilo B Cater; Michael Szarek; Ole Faergeman; John J P Kastelein; Anders G Olsson; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
The American journal of cardiology 2009;103(5):577-82.
2009: Kristel C M C Koeijvoets; Simon P Mooijaart; Geesje M Dallinga-Thie; Joep C Defesche; Ewout W Steyerberg; Rudi G J Westendorp; John J P Kastelein; P Martin van Hagen; Eric J G Sijbrands
Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia.
European heart journal 2009;30(5):618-23.
2009: Jeroen B van der Net; A Cecile J W Janssens; Joep C Defesche; John J P Kastelein; Eric J G Sijbrands; Ewout W Steyerberg
Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia.
The American journal of cardiology 2009;103(3):375-80.
2009: Lysette N Broekhuizen; Hans L Mooij; John J P Kastelein; Erik S G Stroes; Jurgen van Teeffelen; Max Nieuwdorp
Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease.
Current opinion in lipidology 2009;20(1):57-62.
2009: Sander I van Leuven; Rakesh S Birjmohun; R Franssen; Radjesh J Bisoendial; Hanneke de Kort; Johannes Levels; R L Basser; Joost C M Meijers; J A Kuivenhoven; John J P Kastelein; Erik S G Stroes
ApoAI-phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans.
Journal of thrombosis and haemostasis : JTH 2009;7(2):347-54.
2009: Raaj R Sankatsing; Ferdinand W Wit; Martin Vogel; Eric de Groot; Kees Brinkman; Juergen K Rockstroh; John J P Kastelein; Erik S G Stroes; Peter Reiss
Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors.
Atherosclerosis 2009;202(2):589-95.
2009: Karim El Harchaoui; Benoit J Arsenault; Remco Franssen; Jean-Pierre Després; G Kees Hovingh; Erik S G Stroes; James D Otvos; Nicholas J Wareham; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
High-density lipoprotein particle size and concentration and coronary risk.
Annals of internal medicine 2009;150(2):84-93.
2009: Diederik F van Wijk; Erik S G Stroes; John J P Kastelein
Lipid measures and cardiovascular disease prediction.
Disease markers 2009;26(5-6):209-16.
2009: Rakesh S Birjmohun; Menno Vergeer; Erik S G Stroes; Manjinder S Sandhu; Sally L Ricketts; Michael W T Tanck; Nicholas J Wareham; J Wouter Jukema; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study.
PloS one 2009;4(8):e6809.
2008: Menno Vergeer; Michiel Bots; Sander I van Leuven; Dick C Basart; Eric J G Sijbrands; Gregory Evans; Diederick Grobbee; Frank L J Visseren; Anton F Stalenhoef; Erik S G Stroes; John J P Kastelein
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Circulation 2008;118(24):2515-22.
2008: Rakesh S Birjmohun; G Kees Hovingh; Erik S G Stroes; Jorit J Hofstra; Geesje M Dallinga-Thie; Joost C M Meijers; John J P Kastelein; Marcel Levi
Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema.
Clinical therapeutics 2008;30(12):2314-23.
2008: Gurdeep S Sagoo; Iain Tatt; Georgia Salanti; Adam S Butterworth; Nadeem Sarwar; Merel van Maarle; J Wouter Jukema; Björn Wiman; John J P Kastelein; Anna M Bennet; Ulf de Faire; John Danesh; Julian P T Higgins
Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis.
American journal of epidemiology 2008;168(11):1233-46.
2008: Kristel C M C Koeijvoets; Jeroen B van der Net; Elisabeth F C van Rossum; Ewout W Steyerberg; Joep C Defesche; John J P Kastelein; Steven W J Lamberts; Eric J G Sijbrands
Two common haplotypes of the glucocorticoid receptor gene are associated with increased susceptibility to cardiovascular disease in men with familial hypercholesterolemia.
The Journal of clinical endocrinology and metabolism 2008;93(12):4902-8.
2008: Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
The New England journal of medicine 2008;359(21):2195-207.
2008: Liam R Brunham; John J P Kastelein; Michael R Hayden
ABCA1 gene mutations, HDL cholesterol levels, and risk of ischemic heart disease.
JAMA : the journal of the American Medical Association 2008;300(17):1997-8; author reply 1998.
2008: Jakub J Regieli; J Wouter Jukema; Diederick Grobbee; John J P Kastelein; Jan Albert Kuivenhoven; Aeilko H Zwinderman; Yolanda van der Graaf; Michiel Bots; Pieter A Doevendans
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
European heart journal 2008;29(22):2792-9.
2008: Maartje E Visser; Lily Jakulj; John J P Kastelein; Erik S G Stroes
LDL-C-lowering therapy: current and future therapeutic targets.
Current cardiology reports 2008;10(6):512-20.
2008: Anouk van der Graaf; Cynthia Cuffie-Jackson; Maud N Vissers; Mieke D Trip; Claude Gagné; Genming Shi; Enrico Veltri; Hans J Avis; John J P Kastelein
Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.
Journal of the American College of Cardiology 2008;52(17):1421-9.
2008: S Matthijs Boekholdt; Robbert J De Winter; John J P Kastelein
Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?
Circulation 2008;118(11):1120-2.
2008: Remco Franssen; Houshang Monajemi; Erik S G Stroes; John J P Kastelein
Obesity and dyslipidemia.
Endocrinology and metabolism clinics of North America 2008;37(3):623-33, viii.
2008: Jeroen B van der Net; Daniëlla M Oosterveer; Jorie Versmissen; Joep C Defesche; Mojgan Yazdanpanah; Bradley E Aouizerat; Ewout W Steyerberg; Mary J Malloy; Clive R Pullinger; John J P Kastelein; John P Kane; Eric J G Sijbrands
Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia.
European heart journal 2008;29(18):2195-201.
2008: Jeroen B van der Net; A Cecile J W Janssens; Marinus Eijkemans; John J P Kastelein; Eric J G Sijbrands; Ewout W Steyerberg
Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies.
European journal of human genetics : EJHG 2008;16(9):1111-6.
2008: Bernadette A C van Acker; Gert-Jan Botma; Aeilko H Zwinderman; Jan Albert Kuivenhoven; Geesje M Dallinga-Thie; Eric J G Sijbrands; Jolanda M A Boer; jacob seidell; J Wouter Jukema; John J P Kastelein; Hans Jansen; Adrie J M Verhoeven
High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants.
Atherosclerosis 2008;200(1):161-7.
2008: Maud N Vissers; Mieke D Trip; P Haydn Pritchard; Patrick Tam; Tatjana Lukic; Monique G M de Sain-Van Der Velden; Martina de Barse; John J P Kastelein
Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia.
European journal of clinical pharmacology 2008;64(7):651-61.
2008: Fatima Akdim; John J P Kastelein; Daniel Gaudet
The ENHANCE study and marketing ezetimibe.
JAMA : the journal of the American Medical Association 2008;299(23):2747; author reply 2747-8.
2008: John J P Kastelein; Wim A van der Steeg; Ingar Holme; Michael Gaffney; Nilo B Cater; Philip Barter; Prakash Deedwania; Anders G Olsson; S Matthijs Boekholdt; David A Demicco; Michael Szarek; John C LaRosa; Terje R Pedersen; Scott M Grundy
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
Circulation 2008;117(23):3002-9.
2008: Anouk van der Graaf; Jessica Rodenburg; Maud N Vissers; Barbara A Hutten; Albert Wiegman; Mieke D Trip; Erik S G Stroes; Frits A Wijburg; James D Otvos; John J P Kastelein
Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia.
The Journal of pediatrics 2008;152(6):873-8.
2008: Menno Vergeer; John J P Kastelein
Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia.
Nature clinical practice. Cardiovascular medicine 2008;5(6):302-3.
2008: Jeroen B van der Net; Jeroen van Etten; Mojgan Yazdanpanah; Geesje M Dallinga-Thie; John J P Kastelein; Joep C Defesche; Richard P Koopmans; Ewout W Steyerberg; Eric J G Sijbrands
Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia.
European heart journal 2008;29(11):1370-6.
2008: Sanjiv J Shah; David D Waters; Philip Barter; John J P Kastelein; James Shepherd; Nanette K Wenger; David A DeMicco; Andrei Breazna; John C LaRosa
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Journal of the American College of Cardiology 2008;51(20):1938-43.
2008: Anouk van der Graaf; Sigrid W Fouchier; Maud N Vissers; Joep C Defesche; Albert Wiegman; Raaj R Sankatsing; Barbara A Hutten; Mieke D Trip; John J P Kastelein
Familial defective apolipoprotein B and familial hypobetalipoproteinemia in one family: two neutralizing mutations.
Annals of internal medicine 2008;148(9):712-4.
2008: James Shepherd; John J P Kastelein; Vera Bittner; Prakash Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea Zuckerman; Nanette K Wenger
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Journal of the American College of Cardiology 2008;51(15):1448-54.
2008: John J P Kastelein; Fatima Akdim; Erik S G Stroes; Aeilko H Zwinderman; Michiel Bots; Anton F H Stalenhoef; Frank L J Visseren; Eric J G Sijbrands; Mieke D Trip; Evan A Stein; Daniel Gaudet; Raphael Duivenvoorden; Enrico Veltri; Adrian David Marais; Eric de Groot
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
The New England journal of medicine 2008;358(14):1431-43.
2008: Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Josep Rodés-Cabau; Christopher P Cannon; John E Deanfield; Jean-Pierre Després; John J P Kastelein; Steven R Steinhubl; Samir Kapadia; Muhammad Yasin; Witold Ruzyllo; Christophe Gaudin; Bernard Job; Bo Hu; Deepak L Bhatt; A Michael Lincoff; E Murat Tuzcu
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
JAMA : the journal of the American Medical Association 2008;299(13):1547-60.
2008: Roeland Huijgen; Maud N Vissers; Joep C Defesche; Peter J Lansberg; John J P Kastelein; Barbara A Hutten
Familial hypercholesterolemia: current treatment and advances in management.
Expert review of cardiovascular therapy 2008;6(4):567-81.
2008: John J P Kastelein; Eric de Groot
Ultrasound imaging techniques for the evaluation of cardiovascular therapies.
European heart journal 2008;29(7):849-58.
2008: Marijn C Meuwese; Mieke D Trip; Sanne van Wissen; Joram N I van Miert; John J P Kastelein; Erik S G Stroes
Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia.
Atherosclerosis 2008;197(2):916-21.
2008: Max Nieuwdorp; Marijn C Meuwese; Hans L Mooij; Can Ince; Lysette N Broekhuizen; John J P Kastelein; Erik S G Stroes; Hans Vink
Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability.
Journal of applied physiology (Bethesda, Md. : 1985) 2008;104(3):845-52.
2008: Wim A van der Steeg; Ingar Holme; S Matthijs Boekholdt; Mogens Lytken Larsen; Christina Lindahl; Erik S G Stroes; Matti J Tikkanen; Nicholas J Wareham; Ole Faergeman; Anders G Olsson; Terje R Pedersen; Kay-Tee Khaw; John J P Kastelein
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
Journal of the American College of Cardiology 2008;51(6):634-42.
2008: Ingar Holme; Nilo B Cater; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Annals of medicine 2008;40(6):456-64.
2008: Jorie Versmissen; Daniëlla M Oosterveer; Mojgan Yazdanpanah; Joep C Defesche; Dick C G Basart; Anho H Liem; Jan Heeringa; Jacqueline C Witteman; Peter J Lansberg; John J P Kastelein; Eric J G Sijbrands
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
BMJ (Clinical research ed.) 2008;337():a2423.
2008: Karim El Harchaoui; Fatima Akdim; Erik S G Stroes; Mieke D Trip; John J P Kastelein
Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2008;8(4):233-42.
2008: Sander I van Leuven; Erik S G Stroes; John J P Kastelein
High-density lipoprotein: a fall from grace?
Annals of medicine 2008;40(8):584-93.
2008: Sietske J M Homsma; Roeland Huijgen; Saskia Middeldorp; Eric J G Sijbrands; John J P Kastelein
Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance.
European journal of human genetics : EJHG 2008;16(1):14-7.
2008: Sander I van Leuven; R Franssen; John J P Kastelein; Marcel Levi; Erik S G Stroes; P P Tak
Systemic inflammation as a risk factor for atherothrombosis.
Rheumatology (Oxford, England) 2008;47(1):3-7.
2008: Tarek Bouhali; Diane Brisson; Julie St-Pierre; Gérald Tremblay; Patrice Perron; Catherine Laprise; Marie-Claude Vohl; Maud N Vissers; Barbara A Hutten; Jean-Pierre Després; John J P Kastelein; Daniel Gaudet
Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia.
Atherosclerosis 2008;196(1):262-9.
2007: John J P Kastelein
Refocusing on use of cholesteryl ester transfer protein inhibitors.
The American journal of cardiology 2007;100(11 A):n47-52.
2007: Paul M Ridker; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Nardev S Khurmi; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Borge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
The American journal of cardiology 2007;100(11):1659-64.
2007: Raphael Duivenvoorden; Aart J Nederveen; Eric de Groot; John J P Kastelein
Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs.
Current opinion in lipidology 2007;18(6):613-21.
2007: Sander I van Leuven; Rachel Hezemans; Johannes Levels; Susan Snoek; Pieter C F Stokkers; G Kees Hovingh; John J P Kastelein; Erik S G Stroes; Eric de Groot; Daan W Hommes
Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease.
Journal of lipid research 2007;48(12):2640-6.
2007: Radjesh J Bisoendial; John J P Kastelein; Erik S G Stroes
C-reactive protein and atherogenesis: from fatty streak to clinical event.
Atherosclerosis 2007;195(2):e10-8.
2007: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Effects of torcetrapib in patients at high risk for coronary events.
The New England journal of medicine 2007;357(21):2109-22.
2007: Rakesh S Birjmohun; Radjesh J Bisoendial; Sander I van Leuven; Mariëtte T Ackermans; Aelko Zwinderman; John J P Kastelein; Erik S G Stroes; Hans P Sauerwein
A single bolus infusion of C-reactive protein increases gluconeogenesis and plasma glucose concentration in humans.
Metabolism: clinical and experimental 2007;56(11):1576-82.
2007: Benoit J Arsenault; Isabelle Lemieux; Jean-Pierre Després; Nicholas J Wareham; Robert Luben; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study.
European heart journal 2007;28(22):2770-7.
2007: James Shepherd; John J P Kastelein; Vera Bittner; Prakash Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea Zuckerman; Nanette K Wenger
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Clinical journal of the American Society of Nephrology : CJASN 2007;2(6):1131-9.
2007: Rakesh S Birjmohun; Geesje M Dallinga-Thie; Jan Albert Kuivenhoven; Erik S G Stroes; James D Otvos; Nicholas J Wareham; Robert Luben; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Apolipoprotein A-II is inversely associated with risk of future coronary artery disease.
Circulation 2007;116(18):2029-35.
2007: Melchior C Nierman; Jaap Rip; Jan Albert Kuivenhoven; Naohiko Sakai; John J P Kastelein; Monique G M de Sain-Van Der Velden; Erik S G Stroes; Berthil H C M T Prinsen
Enhanced apoB48 metabolism in lipoprotein lipase X447 homozygotes.
Atherosclerosis 2007;194(2):446-51.
2007: Philip J Barter; Antonio M Gotto; John C LaRosa; Jaman Maroni; Michael Szarek; Scott M Grundy; John J P Kastelein; Vera Bittner; Jean-Charles Fruchart
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
The New England journal of medicine 2007;357(13):1301-10.
2007: John C LaRosa; Scott M Grundy; John J P Kastelein; John B Kostis; Heiner Greten
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
The American journal of cardiology 2007;100(5):747-52.
2007: Jaap Rip; Jeroen A Sierts; Stefan F C Vaessen; John J P Kastelein; Jaap Twisk; Jan Albert Kuivenhoven
Adeno-associated virus LPL(S447X) gene therapy in LDL receptor knockout mice.
Atherosclerosis 2007;194(1):55-61.
2007: Jessica Rodenburg; Maud N Vissers; Albert Wiegman; A S Paul van Trotsenburg; Anouk van der Graaf; Eric de Groot; Frits A Wijburg; John J P Kastelein; Barbara A Hutten
Statin treatment in children with familial hypercholesterolemia: the younger, the better.
Circulation 2007;116(6):664-8.
2007: Karim El Harchaoui; Wim A van der Steeg; Erik S G Stroes; John J P Kastelein
The role of CETP inhibition in dyslipidemia.
Current atherosclerosis reports 2007;9(2):125-33.
2007: Fatima Akdim; Erik S G Stroes; John J P Kastelein
Antisense apolipoprotein B therapy: where do we stand?
Current opinion in lipidology 2007;18(4):397-400.
2007: Olaf Schouten; Sanne E Hoeks; Gijs M J M Welten; Jean Davignon; John J P Kastelein; Radosav Vidakovic; Harm H H Feringa; Martin Dunkelgrun; Ron T van Domburg; Jeroen J Bax; Don Poldermans
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
The American journal of cardiology 2007;100(2):316-20.
2007: Marijn C Meuwese; Erik S G Stroes; Stanley L Hazen; Joram N I van Miert; Jan Albert Kuivenhoven; Robert G Schaub; Nicholas J Wareham; Robert Luben; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.
Journal of the American College of Cardiology 2007;50(2):159-65.
2007: Riza C Ozsoy; Wim A van der Steeg; John J P Kastelein; Lambertus Arisz; Marion G Koopman
Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007;22(6):1578-86.
2007: Wim A van der Steeg; S Matthijs Boekholdt; Evan A Stein; Karim El Harchaoui; Erik S G Stroes; Manjinder S Sandhu; Nicholas J Wareham; J Wouter Jukema; Robert Luben; Aeilko H Zwinderman; John J P Kastelein; Kay-Tee Khaw
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
Annals of internal medicine 2007;146(9):640-8.
2007: Rakesh S Birjmohun; Sander I van Leuven; Johannes Levels; Cornelis van 't Veer; Jan Albert Kuivenhoven; Joost C M Meijers; Marcel Levi; John J P Kastelein; Tom van der Poll; Erik S G Stroes
High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(5):1153-8.
2007: John J P Kastelein; Sander I van Leuven; Leslie Burgess; Gregory Evans; Jan Albert Kuivenhoven; Philip J Barter; James H Revkin; Diederick Grobbee; Ward A Riley; Charles L Shear; William T Duggan; Michiel Bots
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
The New England journal of medicine 2007;356(16):1620-30.
2007: John J P Kastelein; Sander I van Leuven; Gregory Evans; Ward A Riley; James H Revkin; Charles L Shear; Michiel Bots
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
Current medical research and opinion 2007;23(4):885-94.
2007: Radjesh J Bisoendial; John J P Kastelein; Stephan L M Peters; Johannes Levels; Rakesh S Birjmohun; Joris Rotmans; Daniel Hartman; Joost C M Meijers; Marcel Levi; Erik S G Stroes
Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects.
Journal of lipid research 2007;48(4):952-60.
2007: Wim A van der Steeg; G Kees Hovingh; Anke H E M Klerkx; Barbara A Hutten; Inge C Nootenboom; Johannes Levels; Arie Van Tol; Geesje M Dallinga-Thie; Aeilko H Zwinderman; John J P Kastelein; Jan Albert Kuivenhoven
Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians.
Journal of lipid research 2007;48(3):674-82.
2007: Karim El Harchaoui; Wim A van der Steeg; Erik S G Stroes; Jan Albert Kuivenhoven; James D Otvos; Nicholas J Wareham; Barbara A Hutten; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Journal of the American College of Cardiology 2007;49(5):547-53.
2007: Kiran K Khush; David D Waters; Vera Bittner; Prakash C Deedwania; John J P Kastelein; Sandra Lewis; Nanette K Wenger
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study.
Circulation 2007;115(5):576-83.
2007: Stefan F C Vaessen; Jaap Twisk; John J P Kastelein; Jan Albert Kuivenhoven
Gene therapy in disorders of lipoprotein metabolism.
Current gene therapy 2007;7(1):35-47.
2007: Olga Souverein; Joep C Defesche; Aeilko H Zwinderman; John J P Kastelein; Michael W T Tanck
Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia.
European heart journal 2007;28(3):299-304.
2007: Fatima Akdim; Sander I van Leuven; John J P Kastelein; Erik S G Stroes
Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?
Current pharmaceutical design 2007;13(10):1003-12.
2007: Fernie J A Penning-van Beest; Fabian Termorshuizen; Wim G Goettsch; Olaf Klungel; John J P Kastelein; Ron Herings
Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study.
European heart journal 2007;28(2):154-9.
2007: Sabine Pinedo; Maud N Vissers; Klaus Von Bergmann; Karim Elharchaoui; Dieter Lütjohann; Robert Luben; Nicholas J Wareham; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study.
Journal of lipid research 2007;48(1):139-44.
2006: Riza C Ozsoy; Sander I van Leuven; John J P Kastelein; Lambertus Arisz; Marion G Koopman
The dyslipidemia of chronic renal disease: effects of statin therapy.
Current opinion in lipidology 2006;17(6):659-66.
2006: David D Waters; John C LaRosa; Philip J Barter; Jean-Charles Fruchart; Antonio M Gotto; Roddy Carter; Andrei Breazna; John J P Kastelein; Scott M Grundy
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
Journal of the American College of Cardiology 2006;48(9):1793-9.
2006: John J P Kastelein; Mark K Wedel; Brenda F Baker; John Su; JoAnn D Bradley; Zhengrong Yu; Emil Chuang; Mark J Graham; Rosanne M Crooke
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.
Circulation 2006;114(16):1729-35.
2006: Jaap Rip; Ko Willems van Dijk; Jeroen A Sierts; John J P Kastelein; Jaap Twisk; Jan Albert Kuivenhoven
AAV1-LPL(S447X) gene therapy reduces hypertriglyceridemia in apoE2 knock in mice.
Biochimica et biophysica acta 2006;1761(10):1163-8.
2006: Kristel C M C Koeijvoets; Elisabeth F C van Rossum; Geesje M Dallinga-Thie; Ewout W Steyerberg; Joep C Defesche; John J P Kastelein; Steven W J Lamberts; Eric J G Sijbrands
A functional polymorphism in the glucocorticoid receptor gene and its relation to cardiovascular disease risk in familial hypercholesterolemia.
The Journal of clinical endocrinology and metabolism 2006;91(10):4131-6.
2006: Prakash Deedwania; Philip J Barter; Rafael Carmena; Jean-Charles Fruchart; Scott M Grundy; Steven M Haffner; John J P Kastelein; John C LaRosa; Holly Schachner; James Shepherd; David D Waters
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Lancet 2006;368(9539):919-28.
2006: Emily S van Aalst-Cohen; Angelique C M Jansen; Michael W T Tanck; Joep C Defesche; Mieke D Trip; Peter J Lansberg; Anton F H Stalenhoef; John J P Kastelein
Diagnosing familial hypercholesterolaemia: the relevance of genetic testing.
European heart journal 2006;27(18):2240-6.
2006: Stefan F C Vaessen; Frank G Schaap; Jan Albert Kuivenhoven; Albert K Groen; Barbara A Hutten; S Matthijs Boekholdt; Hiroaki Hattori; Manjinder S Sandhu; Sheila A Bingham; Robert Luben; Jutta A Palmen; Nicholas J Wareham; Steve E Humphries; John J P Kastelein; Philippa J Talmud; Kay-Tee Khaw
Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study.
Journal of lipid research 2006;47(9):2064-70.
2006: Marijn C Meuwese; Remco Franssen; Erik S G Stroes; John J P Kastelein
And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors.
Current opinion in lipidology 2006;17(4):426-30.
2006: S Matthijs Boekholdt; C Erik Hack; Manjinder S Sandhu; Robert Luben; Sheila A Bingham; Nicholas J Wareham; Ron J G Peters; J Wouter Jukema; Nicholas E Day; John J P Kastelein; Kay-Tee Khaw
C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003.
Atherosclerosis 2006;187(2):415-22.
2006: Mark Roest; Jessica Rodenburg; Albert Wiegman; John J P Kastelein; Hieronymus A M Voorbij
Paraoxonase genotype and carotid intima-media thickness in children with familial hypercholesterolemia.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2006;13(3):464-6.
2006: Anke Hilse Maitland-van der Zee; J Wouter Jukema; Aeilko H Zwinderman; D Michael Hallman; Anthonius de Boer; John J P Kastelein; Peter de Knijff
Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).
Acta cardiologica 2006;61(3):327-31.
2006: Jaap Rip; Melchior C Nierman; Colin J D Ross; J Wouter Jukema; Michael R Hayden; John J P Kastelein; Erik S G Stroes; Jan Albert Kuivenhoven
Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(6):1236-45.
2006: Jessica Rodenburg; Maud N Vissers; Albert Wiegman; Elizabeth R Miller; Paul M Ridker; Joseph L Witztum; John J P Kastelein; Sotirios Tsimikas
Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Journal of the American College of Cardiology 2006;47(9):1803-10.
2006: Colin J D Ross; Jaap Twisk; Andrew C Bakker; Fudan Miao; Dennis Verbart; Jaap Rip; Tamara Godbey; Paul A Dijkhuizen; Wim T Hermens; John J P Kastelein; Jan Albert Kuivenhoven; Janneke M Meulenberg; Michael R Hayden
Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation.
Human gene therapy 2006;17(5):487-99.
2006: Anouk van der Graaf; Barbara A Hutten; John J P Kastelein; Maud N Vissers
Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
Expert review of cardiovascular therapy 2006;4(3):345-51.
2006: Jamal S Rana; Angelique C M Jansen; Aeilko H Zwinderman; Max Nieuwdorp; Emily S van Aalst-Cohen; J Wouter Jukema; Mieke D Trip; John J P Kastelein
Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia.
Diabetes care 2006;29(5):1125-7.
2006: Lily Jakulj; Maud N Vissers; Jessica Rodenburg; Albert Wiegman; Mieke D Trip; John J P Kastelein
Plant stanols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels.
The Journal of pediatrics 2006;148(4):495-500.
2006: Max Nieuwdorp; Hans L Mooij; Jojanneke Kroon; Bektas Atasever; Jos A E Spaan; Can Ince; Frits Holleman; Michaela Diamant; Robert J Heine; J B L Hoekstra; John J P Kastelein; Erik S G Stroes; Hans Vink
Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes.
Diabetes 2006;55(4):1127-32.
2006: Anke H E M Klerkx; Karim El Harchaoui; Wim A van der Steeg; S Matthijs Boekholdt; Erik S G Stroes; John J P Kastelein; Jan Albert Kuivenhoven
Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(4):706-15.
2006: Jaap Rip; Melchior C Nierman; Nicholas J Wareham; Robert Luben; Sheila A Bingham; Nicholas E Day; Joram N I van Miert; Barbara A Hutten; John J P Kastelein; Jan Albert Kuivenhoven; Kay-Tee Khaw; S Matthijs Boekholdt
Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(3):637-42.
2006: Philip J Barter; John J P Kastelein
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Journal of the American College of Cardiology 2006;47(3):492-9.
2006: Max Nieuwdorp; Timon W van Haeften; Mirella C L G Gouverneur; Hans L Mooij; Miriam H P van Lieshout; Marcel Levi; Joost C M Meijers; Frits Holleman; J B L Hoekstra; Hans Vink; John J P Kastelein; Erik S G Stroes
Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo.
Diabetes 2006;55(2):480-6.
2006: Sander I van Leuven; John J P Kastelein; Anthony C Allison; Michael R Hayden; Erik S G Stroes
Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles?
Cardiovascular research 2006;69(2):341-7.
2006: Anneke Kramer; Angelique C M Jansen; Emily S van Aalst-Cohen; Michael W T Tanck; John J P Kastelein; Aeilko H Zwinderman
Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia.
BMC public health 2006;6():262.
2006: Joris W J Vriend; Eric de Groot; Tim T de Waal; Frank M Zijta; John J P Kastelein; Barbara J M Mulder
Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: influence of early repair.
American heart journal 2006;151(1):242-7.
2005: Sigrid W Fouchier; John J P Kastelein; Joep C Defesche
Update of the molecular basis of familial hypercholesterolemia in The Netherlands.
Human mutation 2005;26(6):550-6.
2005: Sigrid W Fouchier; Jessica Rodenburg; Joep C Defesche; John J P Kastelein
Management of hereditary dyslipidaemia; the paradigm of autosomal dominant hypercholesterolaemia.
European journal of human genetics : EJHG 2005;13(12):1247-53.
2005: Lily Jakulj; Mieke D Trip; Thomas Sudhop; Klaus Von Bergmann; John J P Kastelein; Maud N Vissers
Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels.
Journal of lipid research 2005;46(12):2692-8.
2005: Terje R Pedersen; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Fredrik S Bendiksen; Christina Lindahl; Michael Szarek; John Tsai
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2005;294(19):2437-45.
2005: Kristel C M C Koeijvoets; Jessica Rodenburg; Barbara A Hutten; Albert Wiegman; John J P Kastelein; Eric J G Sijbrands
Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial.
Circulation 2005;112(20):3168-73.
2005: John J P Kastelein
Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
The American journal of cardiology 2005;96(9A):20K-27K; discussion 34K-35K.
2005: Jaap Rip; Melchior C Nierman; Jeroen A Sierts; Wilma Petersen; Karin van den Oever; Daniel Van Raalte; Colin J D Ross; Michael R Hayden; Andrew C Bakker; Paul A Dijkhuizen; Wim T Hermens; Jaap Twisk; Erik S G Stroes; John J P Kastelein; Jan Albert Kuivenhoven; Janneke M Meulenberg
Gene therapy for lipoprotein lipase deficiency: working toward clinical application.
Human gene therapy 2005;16(11):1276-86.
2005: Melchior C Nierman; Jaap Rip; Jan Albert Kuivenhoven; Daniel van Raalte; Barbara A Hutten; Naohiko Sakai; John J P Kastelein; Erik S G Stroes
Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance.
Metabolism: clinical and experimental 2005;54(11):1499-503.
2005: Melchior C Nierman; Berthil H C M T Prinsen; Jaap Rip; Robert Jan Veldman; Jan Albert Kuivenhoven; John J P Kastelein; Monique G M de Sain-Van Der Velden; Erik S G Stroes
Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(11):2410-5.
2005: Jamal S Rana; Pascalle S Monraats; Aeilko H Zwinderman; Moniek P M de Maat; John J P Kastelein; Willem R P Agema; Pieter A Doevendans; Robbert J De Winter; René A Tio; Johannes Waltenberger; Rune R Frants; Arnoud van der Laarse; Ernst E van der Wall; J Wouter Jukema
Pre-procedural levels of erythrocyte sedimentation rate (ESR) and risk of clinical restenosis in patients with percutaneous coronary intervention and coronary stent placement.
Thrombosis and haemostasis 2005;94(4):892-4.
2005: Max Nieuwdorp; Marijn C Meuwese; Hans Vink; J B L Hoekstra; John J P Kastelein; Erik S G Stroes
The endothelial glycocalyx: a potential barrier between health and vascular disease.
Current opinion in lipidology 2005;16(5):507-11.
2005: Sander I van Leuven; John J P Kastelein; Michael R Hayden; David d'Cruz; Graham R Hughes; Erik S G Stroes
Cardiovascular disease in systemic lupus erythematosus: has the time for action come?
Current opinion in lipidology 2005;16(5):501-6.
2005: Emily S van Aalst-Cohen; Angelique C M Jansen; S Matthijs Boekholdt; Michael W T Tanck; Marcel R Fontecha; Suzanne Cheng; Jia Li; Joep C Defesche; Jan Albert Kuivenhoven; John J P Kastelein
Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia.
European journal of human genetics : EJHG 2005;13(10):1137-42.
2005: Pascalle S Monraats; Jamal S Rana; Melchior C Nierman; Nuno M M Pires; Aeilko H Zwinderman; John J P Kastelein; Jan Albert Kuivenhoven; Moniek P M de Maat; Saskia Z H Rittersma; Abbey Schepers; Pieter A Doevendans; Robbert J De Winter; René A Tio; Rune R Frants; Paul H A Quax; Arnoud van der Laarse; Ernst E van der Wall; J Wouter Jukema
Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention.
Journal of the American College of Cardiology 2005;46(6):1093-100.
2005: Eric Frisdal; Anke H E M Klerkx; Wilfried Le Goff; Michael W T Tanck; Jean-Pierre Lagarde; J Wouter Jukema; John J P Kastelein; M John Chapman; Maryse Guerin
Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study.
Human molecular genetics 2005;14(18):2607-18.
2005: Joris W J Vriend; Peter Engelfriet; Eric de Groot; Bart M Elsen; John J P Kastelein; Barbara J M Mulder
Age at repair and left ventricular mass in patients after repair of aortic coarctation.
The Journal of thoracic and cardiovascular surgery 2005;130(3):896-7.
2005: Radjesh J Bisoendial; G Kees Hovingh; Karim El Harchaoui; Johannes Levels; Sotirios Tsimikas; Kewei Pu; Aeilko E Zwinderman; Jan Albert Kuivenhoven; John J P Kastelein; Erik S G Stroes
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(9):e133-4.
2005: Raaj R Sankatsing; Sigrid W Fouchier; Stefan de Haan; Barbara A Hutten; Eric de Groot; John J P Kastelein; Erik S G Stroes
Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(9):1979-84.
2005: G Kees Hovingh; Barbara A Hutten; Adriaan G Holleboom; Wilma Petersen; Patrick Rol; Anton F H Stalenhoef; Aeilko H Zwinderman; Eric de Groot; John J P Kastelein; Jan Albert Kuivenhoven
Compromised LCAT function is associated with increased atherosclerosis.
Circulation 2005;112(6):879-84.
2005: Raaj R Sankatsing; Eric de Groot; J Wouter Jukema; Pim J de Feyter; Dudley J Pennell; Paul Schoenhagen; Steven E Nissen; Erik S G Stroes; John J P Kastelein
Surrogate markers for atherosclerotic disease.
Current opinion in lipidology 2005;16(4):434-41.
2005: Angelique C M Jansen; Emily S van Aalst-Cohen; Michael W T Tanck; Suzanne Cheng; Marcel R Fontecha; Jia Li; Joep C Defesche; John J P Kastelein
Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(7):1475-81.
2005: Sander I van Leuven; John J P Kastelein
Atorvastatin.
Expert opinion on pharmacotherapy 2005;6(7):1191-203.
2005: John J P Kastelein; Sigrid W Fouchier; Joep C Defesche
What promise does PCSK9 hold?
Journal of the American College of Cardiology 2005;45(10):1620-1.
2005: Jan Albert Kuivenhoven; Greetje J de Grooth; Hitoshi Kawamura; Anke H E M Klerkx; Francois Wilhelm; Mieke D Trip; John J P Kastelein
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
The American journal of cardiology 2005;95(9):1085-8.
2005: Kristel C M C Koeijvoets; Albert Wiegman; Jessica Rodenburg; Joep C Defesche; John J P Kastelein; Eric J G Sijbrands
Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study.
Atherosclerosis 2005;180(1):93-9.
2005: Jurgen J Wegman; Xiaofeng Hu; Hendra Tan; Arthur A B Bergen; Mieke D Trip; John J P Kastelein; Yvo M Smulders
Patients with premature coronary artery disease who carry the ABCC6 R1141X mutation have no Pseudoxanthoma Elasticum phenotype.
International journal of cardiology 2005;100(3):389-93.
2005: Radjesh J Bisoendial; John J P Kastelein; Johannes Levels; Jaap-Jan Zwaginga; Bas van den Bogaard; Pieter H Reitsma; Joost C M Meijers; Daniel Hartman; Marcel Levi; Erik S G Stroes
Activation of inflammation and coagulation after infusion of C-reactive protein in humans.
Circulation research 2005;96(7):714-6.
2005: John C LaRosa; Scott M Grundy; David D Waters; Charles L Shear; Philip J Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
The New England journal of medicine 2005;352(14):1425-35.
2005: Jamal S Rana; Pascalle S Monraats; Aeilko H Zwinderman; Moniek P M de Maat; John J P Kastelein; Pieter A Doevendans; Robbert J De Winter; René A Tio; Rune R Frants; Arnoud van der Laarse; Ernst E van der Wall; J Wouter Jukema
Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention.
Diabetes care 2005;28(4):873-7.
2005: G Kees Hovingh; Eric de Groot; Wim A van der Steeg; S Matthijs Boekholdt; Barbara A Hutten; Jan Albert Kuivenhoven; John J P Kastelein
Inherited disorders of HDL metabolism and atherosclerosis.
Current opinion in lipidology 2005;16(2):139-45.
2005: S Matthijs Boekholdt; Tymen T Keller; Nicholas J Wareham; Robert Luben; Sheila A Bingham; Nicholas E Day; Manjinder S Sandhu; J Wouter Jukema; John J P Kastelein; C Erik Hack; Kay-Tee Khaw
Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(4):839-46.
2005: Angelique C M Jansen; Emily S van Aalst-Cohen; Barbara A Hutten; Harry R Büller; John J P Kastelein; Martin H Prins
Guidelines were developed for data collection from medical records for use in retrospective analyses.
Journal of clinical epidemiology 2005;58(3):269-74.
2005: Thomas M Van Himbergen; Mark Roest; Jacqueline de Graaf; E H J M Jansen; Hiroaki Hattori; John J P Kastelein; Hieronymus A M Voorbij; Anton F H Stalenhoef; Lambertus J H Van Tits
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia.
Journal of lipid research 2005;46(3):445-51.
2005: John J P Kastelein; Philip T Sager; Eric de Groot; Enrico Veltri
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial.
American heart journal 2005;149(2):234-9.
2005: Mark Roest; Angelique C M Jansen; Arjan D Barendrecht; Frank R Leus; John J P Kastelein; Hieronymus A M Voorbij
Variation at the paraoxonase gene locus contributes to carotid arterial wall thickness in subjects with familial hypercholesterolemia.
Clinical biochemistry 2005;38(2):123-7.
2005: Rakesh S Birjmohun; Barbara A Hutten; John J P Kastelein; Erik S G Stroes
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Journal of the American College of Cardiology 2005;45(2):185-97.
2005: Sanne van Wissen; Tineke J Smilde; Mieke D Trip; Anton F H Stalenhoef; John J P Kastelein
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.
The American journal of cardiology 2005;95(2):264-6.
2005: Joris W J Vriend; Aeiko H Zwinderman; Eric de Groot; John J P Kastelein; Berto J Bouma; Barbara J M Mulder
Predictive value of mild, residual descending aortic narrowing for blood pressure and vascular damage in patients after repair of aortic coarctation.
European heart journal 2005;26(1):84-90.
2004: Christelle Foucher; Stephanie Rattier; David M Flavell; Philippa J Talmud; Steve E Humphries; John J P Kastelein; Amir Ayyobi; Simon Pimstone; Jiri Frohlich; Jean-Claude Ansquer; George Steiner
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
Pharmacogenetics 2004;14(12):823-9.
2004: Jessica Rodenburg; Maud N Vissers; Stephen R Daniels; Albert Wiegman; John J P Kastelein
Lipid-lowering medications.
Pediatric endocrinology reviews : PER 2004;2 Suppl 1():171-80.
2004: Greetje J de Grooth; Anke H E M Klerkx; Erik S G Stroes; Anton F H Stalenhoef; John J P Kastelein; Jan Albert Kuivenhoven
A review of CETP and its relation to atherosclerosis.
Journal of lipid research 2004;45(11):1967-74.
2004: John J P Kastelein
Should rosuvastatin be withdrawn from the market?
Lancet 2004;364(9445):1577-8; author reply 1578-9.
2004: G Kees Hovingh; Alison Brownlie; Radjesh J Bisoendial; Marie Pierre Dube; Johannes Levels; Wilma Petersen; R P F Dullaart; Erik S G Stroes; Aeilko H Zwinderman; Eric de Groot; Michael R Hayden; Jan Albert Kuivenhoven; John J P Kastelein
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease.
Journal of the American College of Cardiology 2004;44(7):1429-35.
2004: Frank van Leth; Praphan Phanuphak; Erik S G Stroes; Brian Gazzard; Pedro Cahn; François Raffi; Robin Wood; Mark Bloch; Christine Katlama; John J P Kastelein; Mauro Schechter; Robert L Murphy; Andrzej Horban; David B Hall; Joep M A Lange; Peter Reiss
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
PLoS medicine 2004;1(1):e19.
2004: James Shepherd; Donald B Hunninghake; Evan A Stein; John J P Kastelein; Susan Harris; John Pears; Howard G Hutchinson
Safety of rosuvastatin.
The American journal of cardiology 2004;94(7):882-8.
2004: Terje R Pedersen; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Fredrik S Bendiksen; Christina Lindahl; Gary Palmer
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
The American journal of cardiology 2004;94(6):720-4.
2004: S Matthijs Boekholdt; Jan Albert Kuivenhoven; Nicholas J Wareham; Ron J G Peters; J Wouter Jukema; Robert Luben; Sheila A Bingham; Nicholas E Day; John J P Kastelein; Kay-Tee Khaw
Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.
Circulation 2004;110(11):1418-23.
2004: Colin J D Ross; Jaap Twisk; Janneke M Meulenberg; Guoqing Liu; Karin van den Oever; Ewoud Moraal; Wim T Hermens; Jaap Rip; John J P Kastelein; Jan Albert Kuivenhoven; Michael R Hayden
Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.
Human gene therapy 2004;15(9):906-19.
2004: Willem R P Agema; Moniek P M de Maat; Aeilko H Zwinderman; John J P Kastelein; ton rabelink; Ad J van Boven; Edith J M Feskens; Judith M Boer; Ernst E van der Wall; J Wouter Jukema
An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men.
Clinical science (London, England : 1979) 2004;107(3):255-61.
2004: Sigrid W Fouchier; Joep C Defesche; John J P Kastelein; Eric J G Sijbrands
Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk.
Seminars in vascular medicine 2004;4(3):259-64.
2004: Anke Hilse Maitland-van der Zee; Olaf Klungel; Hubert G M Leufkens; Anthonius de Boer; Bruno H Ch Stricker; Albert Hofman; Jacqueline C M Witteman; C.M. Duijn; John J P Kastelein
Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism.
Atherosclerosis 2004;175(2):377-9.
2004: Jessica Rodenburg; Maud N Vissers; Albert Wiegman; Mieke D Trip; Henk D Bakker; John J P Kastelein
Familial hypercholesterolemia in children.
Current opinion in lipidology 2004;15(4):405-11.
2004: S Matthijs Boekholdt; Jan Albert Kuivenhoven; G Kees Hovingh; J Wouter Jukema; John J P Kastelein; Arie Van Tol
CETP gene variation: relation to lipid parameters and cardiovascular risk.
Current opinion in lipidology 2004;15(4):393-8.
2004: Albert Wiegman; Barbara A Hutten; Eric de Groot; Jessica Rodenburg; Henk D Bakker; Harry R Büller; Eric J G Sijbrands; John J P Kastelein
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2004;292(3):331-7.
2004: Eric de Groot; G Kees Hovingh; Albert Wiegman; Patrick Duriez; Andries J Smit; Jean-Charles Fruchart; John J P Kastelein
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis.
Circulation 2004;109(23 Suppl 1):III33-8.
2004: Jean-Charles Fruchart; Melchior C Nierman; Erik S G Stroes; John J P Kastelein; Patrick Duriez
New risk factors for atherosclerosis and patient risk assessment.
Circulation 2004;109(23 Suppl 1):III15-9.
2004: Willem R P Agema; J Wouter Jukema; Moniek P M de Maat; Aeilko H Zwinderman; John J P Kastelein; ton rabelink; Ernst E van der Wall
Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
Thrombosis and haemostasis 2004;91(5):986-90.
2004: Joris Rotmans; Hence J M Verhagen; Evelyn Velema; Dominique P V de Kleijn; Mieke van den Heuvel; John J P Kastelein; Gerard Pasterkamp; Erik S G Stroes
Local overexpression of C-type natriuretic peptide ameliorates vascular adaptation of porcine hemodialysis grafts.
Kidney international 2004;65(5):1897-905.
2004: Lambertus J H Van Tits; Tineke J Smilde; Sanne van Wissen; Jacqueline de Graaf; John J P Kastelein; Anton F H Stalenhoef
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2004;52(3):177-84.
2004: Greetje J de Grooth; Tineke J Smilde; Sanne van Wissen; Anke H E M Klerkx; Aeilko H Zwinderman; Jean-Charles Fruchart; John J P Kastelein; Anton F H Stalenhoef; Jan Albert Kuivenhoven
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Atherosclerosis 2004;173(2):261-7.
2004: John J P Kastelein; Eric de Groot; Raaj R Sankatsing
Atherosclerosis measured by B-mode ultrasonography: effect of statin therapy on disease progression.
The American journal of medicine 2004;116 Suppl 6A():31S-36S.
2004: John J P Kastelein; Erik S G Stroes; Eric de Groot
Subclinical atherosclerosis as a target of therapy: potential role of statins.
The American journal of cardiology 2004;93(6):737-40.
2004: Greetje J de Grooth; Kim E Zerba; Shu-Pang Huang; Zenta Tsuchihashi; Todd G Kirchgessner; Rene Belder; Priya Vishnupad; Beihong Hu; Anke H E M Klerkx; Aeilko H Zwinderman; J Wouter Jukema; Frank M Sacks; John J P Kastelein; Jan Albert Kuivenhoven
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
Journal of the American College of Cardiology 2004;43(5):854-7.
2004: David Wonderling; Marina Umans-Eckenhausen; Dalya Marks; Joep C Defesche; John J P Kastelein; Margaret Thorogood
Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
Seminars in vascular medicine 2004;4(1):97-104.
2004: Joep C Defesche; Peter J Lansberg; Marina Umans-Eckenhausen; John J P Kastelein
Advanced method for the identification of patients with inherited hypercholesterolemia.
Seminars in vascular medicine 2004;4(1):59-65.
2004: Emily S van Aalst-Cohen; Angelique C M Jansen; Saskia de Jongh; Pernette R W de Sauvage Nolting; John J P Kastelein
Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia.
Seminars in vascular medicine 2004;4(1):31-41.
2004: Albert Wiegman; Eric de Groot; Barbara A Hutten; Jessica Rodenburg; Johan Gort; Henk D Bakker; Eric J G Sijbrands; John J P Kastelein
Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia.
Lancet 2004;363(9406):369-70.
2004: Heleen E Wiersma; Albert Wiegman; Richard P Koopmans; Henk D Bakker; John J P Kastelein; Chris J van Boxtel
Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia.
Clinical drug investigation 2004;24(2):113-20.
2004: Anke Hilse Maitland-van der Zee; Olaf Klungel; Bruno H Ch Stricker; David L Veenstra; John J P Kastelein; Albert Hofman; Jacqueline C M Witteman; Hubert G M Leufkens; C.M. Duijn; Anthonius de Boer
Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.
Pharmacogenetics 2004;14(1):53-60.
2004: S Matthijs Boekholdt; Ron J G Peters; Moniek P M de Maat; Aeilko H Zwinderman; Ernst E van der Wall; Pieter H Reitsma; J Wouter Jukema; John J P Kastelein
Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events.
American heart journal 2004;147(1):181-6.
2003: Sanne van Wissen; Tineke J Smilde; Eric de Groot; Barbara A Hutten; John J P Kastelein; Anton F H Stalenhoef
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2003;10(6):451-5.
2003: S Matthijs Boekholdt; Ron J G Peters; Katerina Fountoulaki; John J P Kastelein; Eric J G Sijbrands
Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis.
Human genetics 2003;113(5):417-25.
2003: Pernette R W de Sauvage Nolting; Eric de Groot; Aeilko H Zwinderman; Rudolf J A Buirma; Mieke D Trip; John J P Kastelein
Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.
Archives of internal medicine 2003;163(15):1837-41.
2003: Roshni R Singaraja; Liam R Brunham; Henk Visscher; John J P Kastelein; Michael R Hayden
Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(8):1322-32.
2003: Radjesh J Bisoendial; G Kees Hovingh; Johannes Levels; Peter G Lerch; Irmgard Andresen; Michael R Hayden; John J P Kastelein; Erik S G Stroes
Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein.
Circulation 2003;107(23):2944-8.
2003: G Kees Hovingh; Michel J A Van Wijland; Alison Brownlie; Radjesh J Bisoendial; Michael R Hayden; John J P Kastelein; Albert K Groen
The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia.
Journal of lipid research 2003;44(6):1251-5.
2003: Albert Wiegman; Eric J G Sijbrands; Jessica Rodenburg; Joep C Defesche; Saskia de Jongh; Henk D Bakker; John J P Kastelein
The apolipoprotein epsilon4 allele confers additional risk in children with familial hypercholesterolemia.
Pediatric research 2003;53(6):1008-12.
2003: S Matthijs Boekholdt; Willem R P Agema; Ron J G Peters; Aeilko H Zwinderman; Ernst E van der Wall; Pieter H Reitsma; John J P Kastelein; J Wouter Jukema
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Circulation 2003;107(19):2416-21.
2003: Mohamed A Elrayess; Karen E Webb; David M Flavell; Mikko Syvänne; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; J Wouter Jukema; John J P Kastelein; Aeilko H Zwinderman; Steve E Humphries
A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies.
Atherosclerosis 2003;168(1):131-8.
2003: Anke Hilse Maitland-van der Zee; Bruno H Ch Stricker; Olaf Klungel; Aukje K Mantel-Teeuwisse; John J P Kastelein; Albert Hofman; Hubert G M Leufkens; C.M. Duijn; Anthonius de Boer
Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes.
Pharmacogenetics 2003;13(4):219-23.
2003: Albert Wiegman; Jessica Rodenburg; Saskia de Jongh; Joep C Defesche; Henk D Bakker; John J P Kastelein; Eric J G Sijbrands
Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children.
Circulation 2003;107(11):1473-8.
2003: John J P Kastelein; Albert Wiegman; Eric de Groot
Surrogate markers of atherosclerosis: impact of statins.
Atherosclerosis. Supplements 2003;4(1):31-6.
2003: Mieke D Trip; Sanne van Wissen; Tineke J Smilde; Barbara A Hutten; Anton F H Stalenhoef; John J P Kastelein
Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia.
The American journal of cardiology 2003;91(5):604-6.
2003: Anne G Semb; Sanne van Wissen; Thor Ueland; Tineke J Smilde; Torgun Waehre; Mieke D Tripp; Stig S Frøland; John J P Kastelein; Lars Gullestad; Terje R Pedersen; Pål Aukrust; Anton F H Stalenhoef
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Journal of the American College of Cardiology 2003;41(2):275-9.
2003: Anke H E M Klerkx; Michael W T Tanck; John J P Kastelein; Henri O F Molhuizen; J Wouter Jukema; Aeilko H Zwinderman; Jan Albert Kuivenhoven
Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration.
Human molecular genetics 2003;12(2):111-23.
2003: Marina Umans-Eckenhausen; Joep C Defesche; Marjel J van Dam; John J P Kastelein
Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia.
Archives of internal medicine 2003;163(1):65-8.
2002: Saskia de Jongh; Marc R Lilien; Jos op't Roodt; Erik S G Stroes; Henk D Bakker; John J P Kastelein
Early statin therapy restores endothelial function in children with familial hypercholesterolemia.
Journal of the American College of Cardiology 2002;40(12):2117-21.
2002: Marina Umans-Eckenhausen; Eric J G Sijbrands; John J P Kastelein; Joep C Defesche
Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population.
Circulation 2002;106(24):3031-6.
2002: S Matthijs Boekholdt; Mieke D Trip; Ron J G Peters; Marc Engelen; Judith M Boer; Edith J M Feskens; Aeilko H Zwinderman; John J P Kastelein; Pieter H Reitsma
Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(12):e24-7.
2002: Radjesh J Bisoendial; G Kees Hovingh; Eric de Groot; John J P Kastelein; Peter J Lansberg; Erik S G Stroes
Measurement of subclinical atherosclerosis: beyond risk factor assessment.
Current opinion in lipidology 2002;13(6):595-603.
2002: Sanne van Wissen; Mieke D Trip; Tineke J Smilde; Jacqueline de Graaf; Anton F H Stalenhoef; John J P Kastelein
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.
Atherosclerosis 2002;165(2):361-6.
2002: Jacqueline de Graaf; Pernette R W de Sauvage Nolting; Marjel Van Dam; Elizabeth M Belsey; John J P Kastelein; P Haydn Pritchard; Anton F H Stalenhoef
Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels.
The British journal of nutrition 2002;88(5):479-88.
2002: Cheryl L Wellington; Yu-Zhou Yang; Stephen Zhou; Susanne M Clee; Bing Tan; Kenichi Hirano; Karin Zwarts; Anita Kwok; Allison Gelfer; Michel Marcil; Scott Newman; Kirsten Roomp; Roshni R Singaraja; Jennifer Collins; Lin-Hua Zhang; Albert K Groen; Kees Hovingh; Alison Brownlie; Sherrie R Tafuri; Jacques Genest; John J P Kastelein; Michael R Hayden
Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol.
Journal of lipid research 2002;43(11):1939-49.
2002: Saskia de Jongh; Leiv Ose; Tamás Szamosi; Claude Gagné; M Lambert; Russell Scott; Patrice Perron; Dries Dobbelaere; M Saborio; Mary B Tuohy; Michael Stepanavage; Aditi Sapre; Barry Gumbiner; Michele Mercuri; A S Paul van Trotsenburg; Henk D Bakker; John J P Kastelein
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin.
Circulation 2002;106(17):2231-7.
2002: Alan D Attie; Yannick Hamon; Angela R Brooks-Wilson; Mark P Gray-Keller; Marcia L E MacDonald; Veronique Rigot; Angie Tebon; Lin-Hua Zhang; Jacob D Mulligan; Roshni R Singaraja; J James Bitgood; Mark E Cook; John J P Kastelein; Giovanna Chimini; Michael R Hayden
Identification and functional analysis of a naturally occurring E89K mutation in the ABCA1 gene of the WHAM chicken.
Journal of lipid research 2002;43(10):1610-7.
2002: Pernette R W de Sauvage Nolting; Rudolf J A Buirma; Barbara A Hutten; John J P Kastelein
Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH).
Atherosclerosis 2002;164(2):347-54.
2002: Pernette R W de Sauvage Nolting; Marcel B Twickler; Geesje M Dallinga-Thie; Rudolf J A Buirma; Barbara A Hutten; John J P Kastelein
Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy.
Circulation 2002;106(7):788-92.
2002: Mieke D Trip; Yvo M Smulders; Jurgen J Wegman; Xiaofeng Hu; Judith M Boer; Jacoline B ten Brink; Aeilko H Zwinderman; John J P Kastelein; Edith J M Feskens; Arthur A B Bergen
Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease.
Circulation 2002;106(7):773-5.
2002: Anke Hilse Maitland-van der Zee; Olaf Klungel; Bruno H Ch Stricker; W M Monique Verschuren; John J P Kastelein; Hubert G M Leufkens; Anthonius de Boer
Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.
Atherosclerosis 2002;163(2):213-22.
2002: Pernette R W de Sauvage Nolting; Rudolf J A Buirma; Barbara A Hutten; John J P Kastelein
Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]).
The American journal of cardiology 2002;90(2):181-4.
2002: Valerie Evans; John J P Kastelein
Lipoprotein lipase deficiency--rare or common?
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2002;16(4):283-7.
2002: Saskia de Jongh; Marc R Lilien; Henk D Bakker; Barbara A Hutten; John J P Kastelein; Erik S G Stroes
Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia.
Atherosclerosis 2002;163(1):193-7.
2002: Greetje J de Grooth; Jan Albert Kuivenhoven; Anton F H Stalenhoef; Jacqueline de Graaf; Aeilko H Zwinderman; Jan L Posma; Arie Van Tol; John J P Kastelein
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
Circulation 2002;105(18):2159-65.
2002: Marjel van Dam; Sanne van Wissen; John J P Kastelein
Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol.
Journal of cardiovascular risk 2002;9(2):89-95.
2002: Angelique C M Jansen; Sanne van Wissen; Joep C Defesche; John J P Kastelein
Phenotypic variability in familial hypercholesterolaemia: an update.
Current opinion in lipidology 2002;13(2):165-71.
2002: Femke de Beer; Anton F H Stalenhoef; Nicoline Hoogerbrugge; John J P Kastelein; Jan A Gevers Leuven; C.M. Duijn; Louis M Havekes; August Smelt
Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(2):294-9.
2002: Marjel J van Dam; Eric de Groot; Susanne M Clee; G Kees Hovingh; Roosje Roelants; Angela R Brooks-Wilson; Aeilko H Zwinderman; Andries J Smit; August Smelt; Albert K Groen; Michael R Hayden; John J P Kastelein
Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study.
Lancet 2002;359(9300):37-42.
2001: Marc van der Valk; John J P Kastelein; Robert L Murphy; Frank van Leth; Christine Katlama; Andrzej Horban; M Glesby; G Behrens; Bonaventura Clotet; R K Stellato; H O Molhuizen; Peter Reiss
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
AIDS (London, England) 2001;15(18):2407-14.
2001: Willem R P Agema; J Wouter Jukema; S N Pimstone; John J P Kastelein
Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy.
European heart journal 2001;22(22):2058-74.
2001: Susanne M Clee; Odell Loubser; J Collins; John J P Kastelein; Michael R Hayden
The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease.
Clinical genetics 2001;60(4):293-300.
2001: Tineke J Smilde; Sanne van Wissen; Hub Wollersheim; John J P Kastelein; Anton F H Stalenhoef
Genetic and metabolic factors predicting risk of cardiovascular disease in familial hypercholesterolemia.
The Netherlands journal of medicine 2001;59(4):184-95.
2001: Eric J G Sijbrands; R G Westendorp; Joep C Defesche; P H de Meier; August Smelt; John J P Kastelein
Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study.
BMJ (Clinical research ed.) 2001;322(7293):1019-23.
2001: Susanne M Clee; Aeilko H Zwinderman; J C Engert; Karin Zwarts; Henri O F Molhuizen; Kirsten Roomp; J Wouter Jukema; M van Wijland; Marjel J van Dam; T J Hudson; Angela R Brooks-Wilson; Jacques Genest; John J P Kastelein; Michael R Hayden
Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease.
Circulation 2001;103(9):1198-205.
2001: Marjel J van Dam; H J Penn; F R den Hartog; H A Kragten; Mieke D Trip; Rudolf J A Buirma; John J P Kastelein
A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease.
Clinical therapeutics 2001;23(3):467-78.
2001: JM Boer; Edith J M Feskens; Jan Albert Kuivenhoven; EG Schouten; LM Havekes; John J P Kastelein; jacob seidell; Daan Kromhout
Parental history of myocardial infarction: lipid traits, gene polymorphisms and lifestyle.
Atherosclerosis 2001;155(1):149-56.
2001: Tineke J Smilde; Sanne van Wissen; Hub Wollersheim; Mieke D Trip; John J P Kastelein; Anton F H Stalenhoef
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Lancet 2001;357(9256):577-81.
2001: Frank R Leus; M Zwart; John J P Kastelein; Hieronymus A M Voorbij
PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients.
Atherosclerosis 2001;154(3):641-9.
2001: Marina Umans-Eckenhausen; Joep C Defesche; Eric J G Sijbrands; RL Scheerder; John J P Kastelein
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands.
Lancet 2001;357(9251):165-8.
2000: Susanne M Clee; John J P Kastelein; Marjel J van Dam; Michel Marcil; Kirsten Roomp; Karin Zwarts; JA Collins; R Roelants; N Tamasawa; Tomas Stulc; T Suda; R Ceska; Betsie Boucher; C Rondeau; C DeSouich; Angela R Brooks-Wilson; Henri O F Molhuizen; J Frohlich; Jacques Genest; Michael R Hayden
Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes.
The Journal of clinical investigation 2000;106(10):1263-70.
2000: John J P Kastelein; J Wouter Jukema; Aeilko H Zwinderman; S Clee; Ad J van Boven; Hans Jansen; ton rabelink; Ron J G Peters; KI Lie; G Liu; A V G Bruschke; Michael R Hayden
Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group.
Circulation 2000;102(14):1629-33.
2000: Michael H Davidson; Evan A Stein; Donald B Hunninghake; Leiv Ose; Carlos A Dujovne; William Insull; Marcelo C Bertolami; Stuart R Weiss; John J P Kastelein; Russell S Scott; S Campodónico; Ivan D Escobar; Helmut Schrott; Harold E Bays; Michael Stepanavage; M Wu; A C Tate; MR Melino; Debra Kush; Michele Mercuri; Yale B Mitchel
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2000;10(5):253-62.
2000: M J Hoffer; Harold Snieder; S J H Bredie; Pierre N M Demacker; John J P Kastelein; Rune R Frants; Anton F H Stalenhoef
The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia.
Atherosclerosis 2000;151(2):443-50.
2000: Peter J Lansberg; S Tuzgöl; M A van de Ree; Joep C Defesche; John J P Kastelein
[Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands].
Nederlands tijdschrift voor geneeskunde 2000;144(30):1437-40.
2000: Mieke D Trip; Peter J Lansberg; S de Jongh; John J P Kastelein
[Familial hypercholesterolemia: recognition and prevention of cardiac complications at a young age].
Nederlands tijdschrift voor geneeskunde 2000;144(30):1425-8.
2000: John J P Kastelein; Jonathan L Isaacsohn; Leiv Ose; Donald B Hunninghake; J Frohlich; Michael H Davidson; R Habib; Carlos A Dujovne; John R Crouse; M Liu; MR Melino; L O'Grady; Michele Mercuri; Yale B Mitchel
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
The American journal of cardiology 2000;86(2):221-3.
2000: J Wouter Jukema; John J P Kastelein
Tailored therapy to fit individual profiles. Genetics and coronary artery disease.
Annals of the New York Academy of Sciences 2000;902():17-24; discussion 24-6.
2000: Michael R Hayden; Susanne M Clee; Angela R Brooks-Wilson; Jacques Genest; Alan D Attie; John J P Kastelein
Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency.
Current opinion in lipidology 2000;11(2):117-22.
2000: Susanne M Clee; Nagat Bissada; Fudan Miao; L Miao; Adrian David Marais; Howard E Henderson; P Steures; J McManus; Bruce McManus; R C LeBoeuf; John J P Kastelein; Michael R Hayden
Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis.
Journal of lipid research 2000;41(4):521-31.
2000: Eric J G Sijbrands; Rudi G J Westendorp; M Paola Lombardi; Louis M Havekes; Rune R Frants; John J P Kastelein; August Smelt
Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia.
Atherosclerosis 2000;149(2):421-5.
2000: Frank R Leus; M E Wittekoek; J Prins; John J P Kastelein; Hieronymus A M Voorbij
Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia.
Atherosclerosis 2000;149(2):371-7.
2000: Frank L J Visseren; P J Lansberg; D Willem Erkelens; John J P Kastelein
[Statins: possibly more than just lowering of the lipid level].
Nederlands tijdschrift voor geneeskunde 2000;144(7):316-21.
2000: M Paola Lombardi; Egbert J Redeker; Joep C Defesche; Sylvia W A Kamerling; Mieke D Trip; marcel mannens; Louis M Havekes; John J P Kastelein
Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands.
Clinical genetics 2000;57(2):116-24.
2000: Tineke J Smilde; Mieke D Trip; Sanne van Wissen; Hub Wollersheim; John J P Kastelein; Anton F H Stalenhoef
Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia : The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study.
Clinical drug investigation 2000;20(2):67-79.
2000: Leiv Ose; Michael H Davidson; Evan A Stein; John J P Kastelein; Russell S Scott; Donald B Hunninghake; S Campodonico; William Insull; Ivan D Escobar; Helmut Schrott; Michael Stepanavage; M Wu; A C Tate; MR Melino; Michele Mercuri; Yale B Mitchel
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.
Clinical cardiology 2000;23(1):39-46.
2000: Guoqing Liu; KJ Ashbourne-Excoffon; Janet E Wilson; Bruce M McManus; Quinton R Rogers; L Miao; John J P Kastelein; ME Lewis; Michael R Hayden
Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer.
Human gene therapy 2000;11(1):21-32.
1999: ME Wittekoek; Etelka Moll; Simon Pimstone; Mieke D Trip; Peter J Lansberg; Joep C Defesche; J J van Doormaal; Michael R Hayden; John J P Kastelein
A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(11):2708-13.
1999: Michel Marcil; Angela R Brooks-Wilson; Susanne M Clee; Kirsten Roomp; Lin-Hua Zhang; L Yu; JA Collins; Marjel J van Dam; Henri O F Molhuizen; O Loubster; B F Ouellette; Christoph Wilhelm Sensen; Keith Fichter; S Mott; Maxime Denis; Betsie Boucher; Simon Pimstone; Jacques Genest; John J P Kastelein; Michael R Hayden
Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux.
Lancet 1999;354(9187):1341-6.
1999: John J P Kastelein; Jose Ordovas; ME Wittekoek; Simon Pimstone; W F Wilson; SE Gagné; M G Larson; Ernst Schaefer; JM Boer; C Gerdes; Michael R Hayden
Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women.
Clinical genetics 1999;56(4):297-305.
1999: ME Wittekoek; Eric de Groot; Martin H Prins; Mieke D Trip; Harry R Büller; John J P Kastelein
Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease.
Atherosclerosis 1999;146(2):271-9.
1999: L Yu; E Heere-Ress; Betsie Boucher; J C Defesche; John J P Kastelein; M A Lavoie; J Genest
Familial hypercholesterolemia. Acceptor splice site (G-->C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(-1) G-->C].
Atherosclerosis 1999;146(1):125-31.
1999: JM Boer; Jan Albert Kuivenhoven; Edith J M Feskens; EG Schouten; LM Havekes; jacob seidell; John J P Kastelein; Daan Kromhout
Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins.
Clinical genetics 1999;56(2):158-63.
1999: Angela R Brooks-Wilson; Michel Marcil; Susanne M Clee; Lin-Hua Zhang; Kirsten Roomp; Marjel J van Dam; L Yu; Carl G Brewer; JA Collins; Henri O F Molhuizen; Odell Loubser; B F Ouelette; Keith Fichter; KJ Ashbourne-Excoffon; Christoph Wilhelm Sensen; S Scherer; S Mott; Maxime Denis; Duane W Martindale; J Frohlich; K Morgan; BF Koop; Simon Pimstone; John J P Kastelein; Jacques Genest; Michael R Hayden
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency.
Nature genetics 1999;22(4):336-45.
1999: Marianne C Verhaar; RM Wever; John J P Kastelein; D van Loon; S Milstien; Hein A Koomans; ton rabelink
Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial.
Circulation 1999;100(4):335-8.
1999: Marianne C Verhaar; Marina L Honing; T van Dam; M Zwart; Hein A Koomans; John J P Kastelein; ton rabelink
Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids.
Cardiovascular research 1999;42(3):752-60.
1999: SE Gagné; M G Larson; Simon Pimstone; Ernst Schaefer; John J P Kastelein; P W Wilson; Jose Ordovas; Michael R Hayden
A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study.
Clinical genetics 1999;55(6):450-4.
1999: Marina Umans-Eckenhausen; Joep C Defesche; RL Scheerder; F Cliné; John J P Kastelein
[Tracing of patients with familial hypercholesterolemia in the Netherlands].
Nederlands tijdschrift voor geneeskunde 1999;143(22):1157-61.
1999: RM Wever; P Boer; M Hijmering; Erik S G Stroes; Marianne C Verhaar; John J P Kastelein; K Versluis; F Lagerwerf; Herman J M van Rijn; Hein A Koomans; ton rabelink
Nitric oxide production is reduced in patients with chronic renal failure.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(5):1168-72.
1999: Howard E Henderson; John J P Kastelein; Aeilko H Zwinderman; E Gagné; J Wouter Jukema; PW Reymer; BE Groenemeyer; KI Lie; A V G Bruschke; Michael R Hayden; Hans Jansen
Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins.
Journal of lipid research 1999;40(4):735-43.
1998: Joep C Defesche; John J P Kastelein
Molecular epidemiology of familial hypercholesterolaemia.
Lancet 1998;352(9141):1643-4.
1998: Howard E Henderson; S M Bijvoet; marcel mannens; T Bruin; D W Erkelens; Michael R Hayden; John J P Kastelein
Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de novo event.
American journal of medical genetics 1998;78(4):313-6.
1998: J Prins; Y Y van der Hoek; T H Biesheuvel; Frank R Leus; Herman J M van Rijn; John J P Kastelein
The functional and clinical significance of the Met-->Thr substitution in Kringle IV type 10 of apolipoprotein(a).
Thrombosis research 1998;90(3):125-30.
1998: M J Hoffer; S J H Bredie; Harold Snieder; P W Reymer; Pierre N M Demacker; Louis M Havekes; dorret boomsma; Anton F H Stalenhoef; Rune R Frants; John J P Kastelein
Gender-related association between the -93T-->G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia.
Atherosclerosis 1998;138(1):91-9.
1998: T Diekman; P N Demacker; John J P Kastelein; Anton F H Stalenhoef; Wilmar M Wiersinga
Increased oxidizability of low-density lipoproteins in hypothyroidism.
The Journal of clinical endocrinology and metabolism 1998;83(5):1752-5.
1998: ME Wittekoek; Simon Pimstone; PW Reymer; L Feuth; G J Botma; Joep C Defesche; M Prins; Michael R Hayden; John J P Kastelein
A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia.
Circulation 1998;97(8):729-35.
1998: Marianne C Verhaar; RM Wever; John J P Kastelein; T van Dam; Hein A Koomans; ton rabelink
5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia.
Circulation 1998;97(3):237-41.
1998: Jan Albert Kuivenhoven; J Wouter Jukema; Aeilko H Zwinderman; P de Knijff; R McPherson; A V G Bruschke; KI Lie; John J P Kastelein
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
The New England journal of medicine 1998;338(2):86-93.
1998: John J P Kastelein; BE Groenemeyer; D M Hallman; Howard E Henderson; PW Reymer; SE Gagné; Hans Jansen; jacob seidell; Daan Kromhout; J Wouter Jukema; A V G Bruschke; E Boerwinkle; Michael R Hayden
The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group.
Clinical genetics 1998;53(1):27-33.
1997: E Ehrenborg; Susanne M Clee; Simon Pimstone; PW Reymer; Pascale Benlian; CF Hoogendijk; H J Davis; Nagat Bissada; L Miao; SE Gagné; L J Greenberg; R Henry; Howard E Henderson; Jose Ordovas; Ernst Schaefer; John J P Kastelein; Maritha J Kotze; Michael R Hayden
Ethnic variation and in vivo effects of the -93t-->g promoter variant in the lipoprotein lipase gene.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):2672-8.
1997: B E Groenemeijer; M D Hallman; PW Reymer; E Gagné; Jan Albert Kuivenhoven; T Bruin; Hans Jansen; KI Lie; A V G Bruschke; E Boerwinkle; Michael R Hayden; John J P Kastelein
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group.
Circulation 1997;95(12):2628-35.
1997: P Lombardi; Joep C Defesche; Sylvia W A Kamerling; John J P Kastelein; Louis M Havekes
A novel mutation M-21V in exon 1 of the low density lipoprotein receptor gene causing familial hypercholesterolemia.
Clinical genetics 1997;51(6):430-1.
1997: J Prins; Frank R Leus; Y Y van der Hoek; John J P Kastelein; B N Bouma; Herman J M van Rijn
The identification and significance of a Thr-->Pro polymorphism in kringle IV type 8 of apolipoprotein(a).
Thrombosis and haemostasis 1997;77(5):949-54.
1997: Simon Pimstone; Joep C Defesche; Susanne M Clee; Henk D Bakker; Michael R Hayden; John J P Kastelein
Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(5):826-33.
1997: Y Y van der Hoek; Arno Lingenhel; Hans Georg Kraft; Joep C Defesche; John J P Kastelein; Gerd Utermann
Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB.
The Journal of clinical investigation 1997;99(9):2269-73.
1997: P Lombardi; Joep C Defesche; Sylvia W A Kamerling; John J P Kastelein; Louis M Havekes
A novel V415A mutation in exon 9 of the low density lipoprotein receptor gene causing familial hypercholesterolemia.
Clinical genetics 1997;51(4):286-7.
1997: Jan Albert Kuivenhoven; BE Groenemeyer; JM Boer; PW Reymer; R Berghuis; T Bruin; Hans Jansen; jacob seidell; John J P Kastelein
Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(3):595-9.
1997: Jan Albert Kuivenhoven; P de Knijff; JM Boer; H A Smalheer; G J Botma; jacob seidell; John J P Kastelein; P Haydn Pritchard
Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(3):560-8.
1997: Jan Albert Kuivenhoven; Peter Pritchard; J Hill; J Frohlich; G Assmann; John J P Kastelein
The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.
Journal of lipid research 1997;38(2):191-205.
1997: Luc Foubert; T Bruin; Jean Luc de Gennes; E Ehrenborg; J Furioli; John J P Kastelein; Pascale Benlian; Michael R Hayden
A single Ser259Arg mutation in the gene for lipoprotein lipase causes chylomicronemia in Moroccans of Berber ancestry.
Human mutation 1997;10(3):179-85.
1997: H C Knipscheer; I Kindt; A van den Ende; MT Nurmohamed; H Smalbraak; W J Mulder; John J P Kastelein
Magnesium pyridoxal-5'-phosphate glutamate, "A vitamin B6 derivative", does not affect lipoprotein levels in patients with familial hypercholesterolaemia.
European journal of clinical pharmacology 1997;51(6):499-503.
1997: Moniek P M de Maat; H C Knipscheer; John J P Kastelein; Cornelis Kluft
Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
Thrombosis and haemostasis 1997;77(1):75-9.
1997: Erik S G Stroes; John J P Kastelein; F Cosentino; WD Erkelens; RM Wever; Hein A Koomans; TF Lüscher; ton rabelink
Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.
The Journal of clinical investigation 1997;99(1):41-6.
1996: P Lombardi; Sylvia W A Kamerling; Joep C Defesche; John J P Kastelein; Louis M Havekes
Identification of a double mutation in the low-density lipoprotein receptor gene causing familial hypercholesterolemia.
Clinical genetics 1996;50(6):525-6.
1996: S M Bijvoet; Heiko Wiebusch; Y Ma; PW Reymer; T Bruin; Henk D Bakker; Harald Funke; G Assmann; Michael R Hayden; John J P Kastelein
Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250-->Asn; Ser251-->Cys) resulting in lipoprotein lipase (LPL) deficiency.
The Netherlands journal of medicine 1996;49(5):189-95.
1996: J Wouter Jukema; Ad J van Boven; B Groenemeijer; A H Zwinderman; Johan H C Reiber; A V G Bruschke; J A Henneman; G P Molhoek; T Bruin; Hans Jansen; E Gagné; Michael R Hayden; John J P Kastelein
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Circulation 1996;94(8):1913-8.
1996: Jan Albert Kuivenhoven; H Weibusch; P Haydn Pritchard; Harald Funke; Rob Benne; G Assmann; John J P Kastelein
An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease).
The Journal of clinical investigation 1996;98(2):358-64.
1996: H C Knipscheer; C C Boelen; John J P Kastelein; Denise Van Diermen; B E Groenemeijer; A van den Ende; Harry R Büller; Henk D Bakker
Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.
Pediatric research 1996;39(5):867-71.
1996: S Bijvoet; SE Gagné; Sital Moorjani; Claude Gagné; Howard E Henderson; J C Fruchart; J Dallongeville; P Alaupovic; M Prins; John J P Kastelein; Michael R Hayden
Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency.
Journal of lipid research 1996;37(3):640-50.
1996: Jan Albert Kuivenhoven; A F Stalenhoef; J S Hill; P N Demacker; a Errami; John J P Kastelein; P Haydn Pritchard
Two novel molecular defects in the LCAT gene are associated with fish eye disease.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(2):294-303.
1996: Heiko Wiebusch; Harald Funke; T Bruin; H Bucher; Arnold von Eckardstein; John J P Kastelein; Gerd Assmann
Compound heterozygosity for a known (D250N) and a novel (E410K) missense mutation in the C-terminal domain of lipoprotein lipase causes familial chylomicronemia.
Human mutation 1996;8(4):381-3.
1996: A van den Ende; Y Y van der Hoek; John J P Kastelein; Marlys L Koschinsky; C Labeur; M Rosseneu
Lipoprotein [a].
Advances in clinical chemistry 1996;32():73-134.
1995: Jan Albert Kuivenhoven; E J van Voorst tot Voorst; H Wiebusch; S M Marcovina; Harald Funke; G Assmann; P Haydn Pritchard; John J P Kastelein
A unique genetic and biochemical presentation of fish-eye disease.
The Journal of clinical investigation 1995;96(6):2783-91.
1995: Simon Pimstone; SE Gagné; Claude Gagné; Paul J Lupien; Daniel Gaudet; R R Williams; Maritha J Kotze; PW Reymer; Joep C Defesche; John J P Kastelein
Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(10):1704-12.
1995: H Zhang; PW Reymer; M S Liu; I J Forsythe; B E Groenemeyer; J Frohlich; J D Brunzell; John J P Kastelein; Michael R Hayden; Y Ma
Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291-->Ser mutation in the human LPL gene.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(10):1695-703.
1995: P J Lansberg; Y B Mitchel; D Shapiro; John J P Kastelein; R Altman; G Jerums; K Bolzano; S Giannini; J Davignon; P DeWailly
Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients.
Atherosclerosis 1995;116(2):153-62.
1995: PW Reymer; B E Groenemeyer; R van de Burg; John J P Kastelein
Apolipoprotein E genotyping on agarose gels.
Clinical chemistry 1995;41(7):1046-7.
1995: PW Reymer; E Gagné; B E Groenemeyer; H Zhang; I Forsyth; Hans Jansen; jacob seidell; Daan Kromhout; K E Lie; John J P Kastelein
A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis.
Nature genetics 1995;10(1):28-34.
1995: P Lombardi; Eric J G Sijbrands; K van de Giessen; August Smelt; John J P Kastelein; Rune R Frants; Louis M Havekes
Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing.
Journal of lipid research 1995;36(4):860-7.
1994: Y Y van der Hoek; Waheed Sangrar; Graham P Côté; John J P Kastelein; Marlys L Koschinsky
Binding of recombinant apolipoprotein(a) to extracellular matrix proteins.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(11):1792-8.
1994: H C Knipscheer; M T Nurmohamed; A Van den Ende; B Plaat; H J Pruijs; W J Mulder; John J P Kastelein
Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
Journal of internal medicine 1994;236(4):377-84.
1994: S Tuzgöl; S M Bijvoet; T Bruin; John J P Kastelein; Michael R Hayden
Apolipoprotein CII-Padova (Tyr37-->stop) as a cause of chylomicronaemia in an Italian kindred from Siculiana.
Journal of medical genetics 1994;31(8):622-6.
1994: T Bruin; N B Groot; J Jansen; John J P Kastelein
The C-terminus of lipoprotein lipase is essential for biological function but contains no domain for glycosylphosphatidylinositol anchoring.
European journal of biochemistry / FEBS 1994;221(3):1019-25.
1994: A J Van den Broek; L Hollaar; H I Schaefer; Arnoud van der Laarse; H Schuster; J C Defesche; John J P Kastelein; F M Van 't Hooft
Screening for familial defective apolipoprotein B-100 with improved U937 monocyte proliferation assay.
Clinical chemistry 1994;40(3):395-9.
1994: S M Bijvoet; T Bruin; S Tuzgöl; Henk D Bakker; Michael R Hayden; John J P Kastelein
Homozygosity for a mutation in the lipoprotein lipase gene (Gly139-->Ser) causes chylomicronaemia in a boy of Spanish descent.
Human genetics 1994;93(3):339-43.
1994: Y Y van der Hoek; John J P Kastelein; Marlys L Koschinsky
Analysis of structure--function relationships in human apolipoprotein(a).
Canadian journal of physiology and pharmacology 1994;72(3):304-10.
1994: T Bruin; S Tuzgöl; W J Mulder; A E van den Ende; Hans Jansen; Michael R Hayden; John J P Kastelein
A compound heterozygote for lipoprotein lipase deficiency, Val69-->Leu and Gly188-->Glu: correlation between in vitro LPL activity and clinical expression.
Journal of lipid research 1994;35(3):438-45.
1993: T Bruin; S Tuzgöl; Denise Van Diermen; N Hoogerbrugge-van der Linden; J D Brunzell; Michael R Hayden; John J P Kastelein
Recurrent pancreatitis and chylomicronemia in an extended Dutch kindred is caused by a Gly154-->Ser substitution in lipoprotein lipase.
Journal of lipid research 1993;34(12):2109-19.
1993: Joep C Defesche; Denise Van Diermen; P J Lansberg; R J Lamping; PW Reymer; Michael R Hayden; John J P Kastelein
South African founder mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia in the Dutch population.
Human genetics 1993;92(6):567-70.
1993: Joep C Defesche; K L Pricker; Michael R Hayden; B E van der Ende; John J P Kastelein
Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia.
Archives of internal medicine 1993;153(20):2349-56.
1993: Howard E Henderson; Y Ma; M S Liu; I Clark-Lewis; Dennis L Maeder; John J P Kastelein; J D Brunzell; Michael R Hayden
Structure-function relationships of lipoprotein lipase: mutation analysis and mutagenesis of the loop region.
Journal of lipid research 1993;34(9):1593-602.
1993: Michael R Hayden; John J P Kastelein; Harald Funke; J D Brunzell; Y Ma
Phenotypic variation of mutations in the human lipoprotein-lipase gene.
Biochemical Society transactions 1993;21(2):506-9.
1993: Y Y van der Hoek; M E Wittekoek; U Beisiegel; John J P Kastelein; Marlys L Koschinsky
The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms.
Human molecular genetics 1993;2(4):361-6.
1993: Joep C Defesche; P J Lansberg; PW Reymer; R J Lamping; John J P Kastelein
Analysis of the Afrikaner mutation in exon 9 of the low-density lipoprotein receptor gene in a large Dutch kindred suffering from familial hypercholesterolaemia.
The Netherlands journal of medicine 1993;42(1-2):53-60.
1993: S M Bijvoet; T Bruin; John J P Kastelein
The familial hyperchylomicronaemia syndrome.
The Netherlands journal of medicine 1993;42(1-2):36-44.
1992: Joep C Defesche; M A van de Ree; John J P Kastelein; Denise Van Diermen; N W Janssens; J J van Doormaal; Michael R Hayden
Detection of the Pro664-Leu mutation in the low-density lipoprotein receptor and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from The Netherlands and Canada.
Clinical genetics 1992;42(6):273-80.
1992: T Bruin; John J P Kastelein; Denise Van Diermen; Y Ma; Howard E Henderson; P M Stuyt; A F Stalenhoef; Augueste Sturk; J D Brunzell; Michael R Hayden
A missense mutation Pro157 Arg in lipoprotein lipase (LPLNijmegen) resulting in loss of catalytic activity.
European journal of biochemistry / FEBS 1992;208(2):267-72.
1992: Y Ma; B I Wilson; S Bijvoet; Howard E Henderson; E Cramb; G Roederer; M R Ven Murthy; Pierre Julien; H D Bakker; John J P Kastelein
A missense mutation (Asp250----Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries.
Genomics 1992;13(3):649-53.
1992: E Dekker; H R Büller; John J P Kastelein
[Postmenopausal estrogen substitution and the risk of atherosclerotic heart and vascular diseases].
Nederlands tijdschrift voor geneeskunde 1992;136(25):1197-200.
1992: P J Lansberg; John J P Kastelein; Joep C Defesche; J W ten Cate
[The treatment of familial hypercholesterolemia].
Nederlands tijdschrift voor geneeskunde 1992;136(15):734-8.
1992: John J P Kastelein; T Bruin; J W ten Cate
[Lipoprotein lipase].
Nederlands tijdschrift voor geneeskunde 1992;136(15):727-30.
1992: John J P Kastelein; P Haydn Pritchard; D W Erkelens; Jan Albert Kuivenhoven; J J Albers; J J Frohlich
Familial high-density-lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent.
Journal of internal medicine 1992;231(4):413-9.
1992: Y H Ma; T Bruin; S Tuzgol; B I Wilson; G Roederer; M S Liu; J Davignon; John J P Kastelein; J D Brunzell; Michael R Hayden
Two naturally occurring mutations at the first and second bases of codon aspartic acid 156 in the proposed catalytic triad of human lipoprotein lipase. In vivo evidence that aspartic acid 156 is essential for catalysis.
The Journal of biological chemistry 1992;267(3):1918-23.
1991: T Bruin; PW Reymer; B E Groenemeyer; P J Talmud; John J P Kastelein
HindIII-polymorphism in the LPL-gene detected by PCR.
Nucleic acids research 1991;19(22):6346.
1991: Harald Funke; Arnold von Eckardstein; Peter Pritchard; J J Albers; John J P Kastelein; C Droste; Gerd Assmann
A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(11):4855-9.
1991: J W Gorter; P P Schilte; P J Lansberg; John J P Kastelein; Henk D Bakker
[A patient with the homozygote form of familial hypercholesterolemia].
Tijdschrift voor kindergeneeskunde 1991;59(3):88-91.
1991: Henk D Bakker; T Bruin; Marianne C L Schaap; P J Lansberg; John J P Kastelein
The prediction of the therapeutic response to cholesterol lowering drugs in an 11-year-old boy with homozygous familial hypercholesterolaemia.
Journal of inherited metabolic disease 1991;14(3):389-92.
1990: Maria Victoria Monsalve; Howard E Henderson; G Roederer; Pierre Julien; S Deeb; John J P Kastelein; L Peritz; R Devlin; T Bruin; M R Murthy
A missense mutation at codon 188 of the human lipoprotein lipase gene is a frequent cause of lipoprotein lipase deficiency in persons of different ancestries.
The Journal of clinical investigation 1990;86(3):728-34.
1990: John J P Kastelein; Jonathan L Haines; Michael R Hayden
The gene causing familial hypoalphalipoproteinemia is not caused by a defect in the apo AI-CIII-AIV gene cluster in a Spanish family.
Human genetics 1990;84(5):396-400.
1989: Sylvie Langlois; S Deeb; J D Brunzell; John J P Kastelein; Michael R Hayden
A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(3):948-52.
1988: Sylvie Langlois; John J P Kastelein; Michael R Hayden
Characterization of six partial deletions in the low-density-lipoprotein (LDL) receptor gene causing familial hypercholesterolemia (FH).
American journal of human genetics 1988;43(1):60-8.
1988: Michael R Hayden; J Hewitt; J J Wasmuth; John J P Kastelein; Sylvie Langlois; M Conneally; Jonathan L Haines; B Smith; C Hilbert; D Allard
A polymorphic DNA marker that represents a conserved expressed sequence in the region of the Huntington disease gene.
American journal of human genetics 1988;42(1):125-31.
1985: C Beyer; L W Statius van Eps; John J P Kastelein; D P M Brandjes; W M Mairuhu; Abraham E van den Ende
Urinary creatine: biochemical indicator for evaluation of sickle cell crises.
Clinical chemistry 1985;31(7):1232-4.